var title_f8_53_9040="HSG showing endometrial polyps";
var content_f8_53_9040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram showing multiple filling defects due to endometrial polyps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baramki, TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright &copy; 2005 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9040=[""].join("\n");
var outline_f8_53_9040=null;
var title_f8_53_9041="Phenprocoumon: International drug information";
var content_f8_53_9041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenprocoumon: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12617216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Falithrom (DE);",
"     </li>",
"     <li>",
"      Marcoumar (AT, BE, BR, DK, DE, NL, CH);",
"     </li>",
"     <li>",
"      Marcumar (DE);",
"     </li>",
"     <li>",
"      Marcuphen (DE);",
"     </li>",
"     <li>",
"      Phenpro Abz (DE);",
"     </li>",
"     <li>",
"      Phenprogamma (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F12617232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Fenprocumone;",
"     </li>",
"     <li>",
"      Phenprocoumarol;",
"     </li>",
"     <li>",
"      Phenprocoumarole;",
"     </li>",
"     <li>",
"      Phenprocoumone;",
"     </li>",
"     <li>",
"      Phenprocumone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F12617240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticoagulant, Coumarin Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin K Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F12617298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Usual dose: 6-9 mg once on day 1, followed by 6 mg on day 2; beginning on day 3: 1.5-4.5 mg once daily depending on achievement of target INR",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F12617297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12617299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Tablet: 3 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16450 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-8189A37D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9041=[""].join("\n");
var outline_f8_53_9041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617216\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617232\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617240\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617298\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617297\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617299\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/16450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/16450|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_53_9042="Trochanteric bursa";
var content_f8_53_9042=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trochanteric bursa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomy of the trochanteric bursa. In patients with bursitis, corticosteroid-local anesthetic injections can be made into the site.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9042=[""].join("\n");
var outline_f8_53_9042=null;
var title_f8_53_9043="Pseudallescheria boydii microscopy";
var content_f8_53_9043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudallescheria boydii microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microscopic appearance of cleistothecia, the spherical sexual structures which characterize P. boydii.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Barbara D. Alexander, MD, MHS and Sylvia F. Costa, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9043=[""].join("\n");
var outline_f8_53_9043=null;
var title_f8_53_9044="Chest radiograph of left ventricular aneurysm III";
var content_f8_53_9044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of left ventricular aneurysm III",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain frontal chest radiograph from a 60-year-old male with history of angina and myocardial infarction demonstrates a prominent bulge along the lateral aspect of the left ventricular margin consistent with an aneurysm (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9044=[""].join("\n");
var outline_f8_53_9044=null;
var title_f8_53_9045="Oxandrolone: Patient drug information";
var content_f8_53_9045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxandrolone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"     see \"Oxandrolone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxandrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Call your doctor if you see dark urine, feel tired, are not hungry, have an upset stomach, are throwing up, or have yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may change cholesterol levels and raise your chance of heart disease. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you gain weight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxandrolone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703447",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Breast cancer, high calcium levels, prostate cancer, or very bad kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Emotional ups and downs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, a deep voice, facial hair, pimples, or period changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of suspension not used after 3 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11856 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9045=[""].join("\n");
var outline_f8_53_9045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204321\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027948\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027950\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027949\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027954\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027955\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027957\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027952\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027953\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027958\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027959\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=related_link\">",
"      Oxandrolone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_53_9046="Liposomal daunorubicin: Drug information";
var content_f8_53_9046=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liposomal daunorubicin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/21/25941?source=see_link\">",
"    see \"Liposomal daunorubicin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DaunoXome&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F157224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Anthracycline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F157207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Advanced HIV-associated Kaposi's sarcoma: I.V.: 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F157208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F157209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     1.2-3 mg/dL: Reduce dose to 75% of normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;3 mg/dL: Reduce dose to 50% of normal.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F157210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum bilirubin 1.2-3 mg/dL: Reduce to 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum bilirubin &gt;3 mg/dL: Reduce to 50% of normal dose.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F4426084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Withhold treatment for ANC &lt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DaunoXome&reg;: 2 mg/mL (25 mL) [contains sucrose 2125 mg/25 mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F157192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse over 1 hour; do not mix with other drugs. Avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F157229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"     <b>",
"      Incompatible",
"     </b>",
"     with normal saline, sodium bicarbonate and fluorouracil, heparin, dexamethasone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F157190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     First-line treatment of advanced HIV-associated Kaposi's sarcoma (KS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F157231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DAUNOrubicin liposomal may be confused with DACTINomycin, DOXOrubicin, DOXOrubicin liposomal, epirubicin, IDArubicin, valrubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Liposomal formulation (DaunoXome&reg;) may be confused with the conventional formulation (Cerubidine&reg;, Rubex&reg;)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F157222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (49%), fever (47%), headache (25%), neutropenic fever (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (54%), diarrhea (38%), abdominal pain (23%), anorexia (23%), vomiting (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression (onset: 7 days; nadir: 14 days; recovery 21 days), neutropenia (up to 55%; grade 4: 15%), anemia (up to 55%; grade 4: 2%), thrombocytopenia (up to 12%; grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Rigors (19%), back pain (16%), neuropathy (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (28%), dyspnea (26%), rhinitis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Opportunistic infections (40%), allergic reactions (24%), diaphoresis (14%), infusion-related reactions (14%; includes back pain, flushing, chest tightness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (10%), hypertension (&le;5%), palpitation (&le;5%), syncope (&le;5%), tachycardia (&le;5%), LVEF decreased (3%), CHF/cardiomyopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (10%), malaise (10%), dizziness (8%), insomnia (6%), abnormal thinking (&le;5%), amnesia (&le;5%), anxiety (&le;5%), ataxia (&le;5%), confusion (&le;5%), emotional lability (&le;5%), hallucination (&le;5%), meningitis (&le;5%), seizure (&le;5%), somnolence (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (8%), pruritus (7%), dry skin (&le;5%), folliculitis (&le;5%), seborrhea (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (&le;5%), hot flashes (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomatitis (10%), constipation (7%), tenesmus (5%), appetite increased (&le;5%), dental caries (&le;5%), dysphagia (&le;5%), gastrointestinal hemorrhage (&le;5%), gastritis (&le;5%), gingival bleeding (&le;5%), hemorrhoids (&le;5%), melena (&le;5%), splenomegaly (&le;5%), taste perversion (&le;5%), xerostomia (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (&le;5%), nocturia (&le;5%), polyuria (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatomegaly (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site inflammation (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (7%), myalgia (7%), gait abnormal (&le;5%), hyperkinesia (&le;5%), hypertonia (&le;5%), tremor (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision (5%) conjunctivitis (&le;5%), eye pain (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Deafness (&le;5%), earache (&le;5%), tinnitus (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (8%), hemoptysis (&le;5%), pulmonary infiltrate (&le;5%), sputum increased (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (5%), hiccups (&le;5%), lymphadenopathy (&le;5%), thirst (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Angina, atrial fibrillation, cardiac arrest, MI, pericardial effusion, pericardial tamponade, pulmonary hypertension, supraventricular tachycardia, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F157195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to daunorubicin citrate (liposomal), daunorubicin, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F157178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: May cause bone marrow suppression,",
"     </b>",
"     particularly neutropenia; monitor closely for infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions:",
"     <b>",
"      [U.S. Boxed Warning]: The lipid component is associated with infusion-related reactions (back pain, flushing, chest tightness) usually within the first 5 minutes of infusion;",
"     </b>",
"     monitor, interrupt infusion, and resume at reduced infusion rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Monitor cardiac function regularly; especially in patients with previous therapy with high cumulative doses of anthracyclines, cyclophosphamide, or thoracic radiation, or who have pre-existing cardiac disease.",
"     </b>",
"     Although the risk increases with cumulative dose, irreversible cardiotoxicity may occur with anthracycline treatment at any dose level. Patients with pre-existing heart disease, hypertension, concurrent administration of other antineoplastic agents, prior or concurrent chest irradiation, and advanced age are at increased risk. Evaluate left ventricular ejection fraction (LVEF) prior to treatment and periodically during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Use with caution in patients with hepatic impairment;",
"     </b>",
"     dosage reduction is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; may require dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly:  Use with caution in the elderly; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: May diminish the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Antineoplastic Agents (Anthracycline, Systemic) may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: May enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F157185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4426079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects and embryotoxicity were noted in animal studies. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant while receiving treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F157216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (DaunoXome Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (25 mL): $1380.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F157187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets (prior to each dose), liver function tests, renal function tests; evaluate cardiac function (baseline left ventricular ejection fraction [LVEF] prior to treatment initiation; repeat LVEF at total cumulative doses of 320 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , and every 160 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     thereafter; patients with pre-existing cardiac disease, history of prior chest irradiation, or history of prior anthracycline treatment should have baseline LVEF and every 160 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     thereafter); signs and symptoms of infection or disease progression; monitor closely for infusion reactions",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      DaunoXome (AT, DK, FI, FR, GB, IT, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F157177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liposomes have been shown to penetrate solid tumors more effectively, possibly because of their small size and longer circulation time. Once in tissues, daunorubicin is released. Daunorubicin inhibits DNA and RNA synthesis by intercalation between DNA base pairs and by steric obstruction; and intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F157194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 5-8 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Similar to daunorubicin, but metabolite plasma levels are low",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Distribution: 4.4 hours; Terminal: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces; some urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance, plasma: 17.3 mL/minute",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Eckardt JR, Campbell E, Burris HA, et al, &ldquo;A Phase II Trial of DaunoXome&reg;, Liposome-Encapsulated Daunorubicin, in Patients With Metastatic Adenocarcinoma of the Colon,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 1994, 17(6):498-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/53/9046/abstract-text/7977168/pubmed\" id=\"7977168\" target=\"_blank\">",
"        7977168",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill PS, Espina BM, Muggia F, et al, &ldquo;Phase I/II Clinical and Pharmacokinetic Evaluation of Liposomal Daunorubicin,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(4):996-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/53/9046/abstract-text/7707129/pubmed\" id=\"7707129\" target=\"_blank\">",
"        7707129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill PS, Wernz J, Scadden DT, et al, &ldquo;Randomized Phase III Trial of Liposomal Daunorubicin Versus Doxorubicin, Bleomycin, and Vincristine in AIDS-Related Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(8):2353-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/53/9046/abstract-text/8708728/pubmed\" id=\"8708728\" target=\"_blank\">",
"        8708728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guaglianone P, Chan K, Dela Flor-Weiss E, et al, &ldquo;Phase I and Pharmacologic Study of Liposomal Daunorubicin (DaunoXome&reg;),&rdquo;",
"      <i>",
"       Invest New Drugs",
"      </i>",
"      , 1994, 12(2):103-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/53/9046/abstract-text/7860226/pubmed\" id=\"7860226\" target=\"_blank\">",
"        7860226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schurmann D, Dormann A, Grunewald T, et al, &ldquo;Successful Treatment of AIDS-Related Pulmonary Kaposi's Sarcoma With Liposomal Daunorubicin,&rdquo;",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 1994, 7(4):824-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/53/9046/abstract-text/8005268/pubmed\" id=\"8005268\" target=\"_blank\">",
"        8005268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9325 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9046=[""].join("\n");
var outline_f8_53_9046=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708683\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157205\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157224\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157207\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157208\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157209\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157210\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426084\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157189\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157174\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157192\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157229\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157190\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157231\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157222\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157195\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157178\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837878\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157183\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157185\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426079\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157216\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323095\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157187\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539842\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157177\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157194\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9325\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9325|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/21/25941?source=related_link\">",
"      Liposomal daunorubicin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_53_9047="Emergency thoracotomy aortic cross clamp";
var content_f8_53_9047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Emergency thoracotomy showing aortic cross clamp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9047=[""].join("\n");
var outline_f8_53_9047=null;
var title_f8_53_9048="Red blood cell transfusions in the newborn";
var content_f8_53_9048=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Red blood cell transfusions in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/53/9048/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/53/9048/contributors\">",
"     Robin Ohls, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/53/9048/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/53/9048/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/53/9048/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/53/9048/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/53/9048/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/53/9048/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red blood cell (RBC) transfusion provides an immediate increase in oxygen delivery to tissues and is an effective and rapid intervention to treat anemia. RBC transfusions can reduce the morbidity associated with anemia, especially anemia of prematurity, and may be life saving in neonates with severe blood loss.",
"   </p>",
"   <p>",
"    However, transfusion is a temporary measure and has the disadvantages of further inhibiting erythropoiesis and being associated with risks of infection, graft-versus-host disease, transfusion related acute lung injury (TRALI), transfusion associated circulatory overload (TACO), and toxic effects of anticoagulants or preservatives. Deleterious effects specific to neonates such as transfusion related acute gut injury (TRAGI) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/1\">",
"     1",
"    </a>",
"    ] and intraventricular hemorrhage (IVH) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/2\">",
"     2",
"    </a>",
"    ] have been reported. In addition, RBC transfusions may be associated with an increased risk of death, necrotizing enterocolitis, extension of IVH, or transient increase in respiratory support; although there is no evidence for a causal relationship with any of these adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. These potential complications underscore the need to carefully evaluate a neonate's ability to delivery oxygen to tissues prior to ordering a nonemergent transfusion, and to document benefit following the transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=see_link&amp;anchor=H31669350#H31669350\">",
"     \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\", section on 'RBC transfusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is often difficult to distinguish the neonate who is anemic and requires RBC transfusion from one who has adapted to a low hematocrit (Hct), and is best treated conservatively to avoid the associated risks of transfusion.",
"   </p>",
"   <p>",
"    The indications for neonatal RBC transfusions and the selection of the proper blood product will be reviewed here. Anemia of prematurity and indications for red cell transfusion in infants and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=see_link\">",
"     \"Anemia of prematurity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=see_link\">",
"     \"Indications for red blood cell transfusion in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17001196\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia occurs when the red blood cell (RBC) mass does not adequately meet the oxygen demands of the tissue.",
"   </p>",
"   <p>",
"    Oxygen supply to the tissue is defined as the product of cardiac output and arterial oxygen content. The arterial oxygen content is dependent upon the hemoglobin concentration, arterial oxygen saturation, oxygen carrying capacity of hemoglobin (1.34",
"    <span class=\"nowrap\">",
"     mL/gm",
"    </span>",
"    hemoglobin), and to a minor extent, the solubility of oxygen. Oxygen supply is increased by increasing cardiac output, arterial oxygen saturation, or hemoglobin concentration.",
"   </p>",
"   <p>",
"    The indications for neonatal RBC transfusions differ based upon the rate of fall in hemoglobin (acute versus chronic anemia). The need for transfusion in an infant with acute blood loss is generally dependent upon persistent clinical signs of inadequate oxygen delivery following intravascular volume restoration. In chronic anemia, the need for RBC transfusion is, likewise, based upon clinical signs of inadequate oxygen delivery (increased resting heart rate, acidosis, poor growth, and apnea) and the degree of respiratory support needed by the infant. Although target hemoglobin and hematocrit (values below which a RBC transfusion is needed) have been used as clinical indicators for RBC transfusion, it remains uncertain what is the target hematocrit or hemoglobin that optimally balances the risk and benefits of this intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates with significant acute blood loss require immediate fluid resuscitation, but may or may not require a RBC transfusion. For example, term infants may tolerate perinatal blood loss up to one-third of their total blood volume. Infants with a hemoglobin level &ge;10",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    following volume expansion usually have adequate oxygen delivery and generally only require iron supplementation to replace iron losses due to the hemorrhage.",
"   </p>",
"   <p>",
"    Indications for a RBC transfusion in a term or preterm neonate after volume resuscitation with restoration of the effective circulating volume following an acute blood loss include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &gt;20 percent blood loss",
"     </li>",
"     <li>",
"      10 to 20 percent blood with evidence of inadequate oxygen delivery, such as persistent acidosis",
"     </li>",
"     <li>",
"      Ongoing hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to transfusion, it is critical to determine whether an infant born with a significantly low hematocrit was due to an acute fall near the time of delivery or was due to a chronic in-utero process because this may alter the type of transfusion administered (ie, simple versus exchange). For example, in the twin-twin transfusion syndrome or feto-maternal hemorrhage, the degree and timing of bleeding is variable. Bleeding may occur just before delivery or might have begun in the second trimester and be long-standing at the time of delivery, both of which may result in a hematocrit below 20 percent at birth. In the latter case, a partial exchange transfusion should be considered in an infant in whom an increase in tissue oxygen delivery is necessary, because a simple transfusion may cause a significant increase in blood volume resulting in heart failure because these infants often have elevated circulating blood volumes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;All newborn infants have a gradual fall in their hematocrit after birth due to decreased production of erythropoietin, referred to as physiologic anemia. In preterm infants, this decline occurs earlier and is more pronounced in its severity than in term infants. This hyporegenerative anemia associated with low erythropoietin concentrations is referred to as anemia of prematurity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=see_link&amp;anchor=H2#H2\">",
"     \"Anemia of prematurity\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, infants cared for in the neonatal intensive care unit (NICU) are at risk for developing chronic anemia because of blood loss from phlebotomy. This is especially true for very low birth weight (VLBW) infants (birth weight &lt;1500 g) who are often more severely ill and require frequent blood tests and who have a lower total blood volume than more mature, larger neonates. In addition, RBCs in preterm infants have a reduced life span compared with full term infants, which contributes to the anemia of prematurity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Target hemoglobin or hematocrit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Target hemoglobin and hematocrit, values below which a RBC transfusion is needed, have been used universally as clinical indicators for RBC transfusion in neonates, older infants, children, and adults. The clinical approach to transfusions in the newborn with chronic anemia has changed over time. The use of high hematocrit (hemoglobin) triggers (greater than 40 percent), referred to as liberal approach, was standard practice in the 1970s and 1980s. A more restrictive approach emerged in the 1990s, as concerns for the adverse effects of transfusions grew, particularly transmission of infections such as hepatitis B and C, and human immunodeficiency virus. This approach has decreased the transfusion rate in neonates. However, it remains unclear what the minimal target hematocrit or hemoglobin is in neonates that optimally balances the risk and benefits of this intervention.",
"   </p>",
"   <p>",
"    The more restrictive approach was supported by results from a randomized trial studying the effects of erythropoietin (EPO) in preterm infants with birth weights below 1250, which was published in 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/6\">",
"     6",
"    </a>",
"    ]. This study developed transfusion guidelines that used hematocrit triggers ranging from 20 percent in asymptomatic infants to 35 percent in infants who required respiratory support, including supplemental oxygen. Excellent short-term outcomes were noted in infants who were transfused based upon this protocol, demonstrating that premature infants were able to tolerate a gradual decline in hematocrit.",
"   </p>",
"   <p>",
"    Since that initial observation, there have been several trials comparing the outcomes between the use of restrictive (low) versus liberal (high) target hematocrit (Hct) thresholds [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. In a 2011 meta-analysis based on four trials with 614 infants, the following outcomes were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants in the low hemoglobin threshold group received fewer transfusions than those in the high hemoglobin threshold group and donor exposures per infant were also lower in the low hemoglobin threshold group.",
"     </li>",
"     <li>",
"      Infants in the low threshold group were transfused at a later age.",
"     </li>",
"     <li>",
"      There was no difference in the rate of mortality between the low and high hemoglobin threshold groups (relative risk [RR] 1.23, 95% CI 0.86-1.76).",
"     </li>",
"     <li>",
"      There was no difference in the composite outcome of death and serious morbidity, defined as severe retinopathy of prematurity, bronchopulmonary dysplasia, brain injury on ultrasound, at hospital discharge (RR 1.07, 95% 0.96-1.2). In a separate analysis, there was also no difference in the composite outcome of death and severe brain injury at hospital discharge (RR 1.12, 95% CI 0.81-1.55).",
"     </li>",
"     <li>",
"      In one trial (The PINT Study [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/9\">",
"       9",
"      </a>",
"      ]), there was no difference between the low and high target Hct groups at 18 to 21 months corrected age in the composite outcome of death or neurodevelopment impairment, defined as cerebral palsy, significant visual and hear impairment, and a Mental Development Index (MDI) score &lt;70, (45 vs 39 percent, odds ratio [OR] 1.45, 95% CI 0.94-2.21) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/13\">",
"       13",
"      </a>",
"      ]. Of note, this was the largest trial and accounted for 73 percent of the patients in the meta-analysis.",
"     </li>",
"     <li>",
"      There were no significant differences for survivors in secondary outcomes including retinopathy of prematurity, brain injury based on ultrasonography, bronchopulmonary dysplasia, neurosensory impairment at 18 to 21 months of corrected age, apnea requiring intervention, difference in weight gain, length of hospitalization, patent ductus arteriosus, and necrotizing enterocolitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was a fair degree of heterogeneity as the trials differed in the high hemoglobin target thresholds (although the low thresholds were similar) and the birth weight of the enrolled infants. It should be noted that in three of the trials that included almost all of the patients (n = 580 patients), erythropoietin was not given. Nevertheless, the authors concluded that the restrictive (low) transfusion thresholds compared with a liberal (high) threshold resulted in modest reductions in exposure to transfusions, and there were no differences in mortality, major morbidities, and serious neurodevelopmental impairment at 18 to 20 month corrected age. Because the low thresholds were similar amongst the four trials, the authors recommended the following lower levels of hemoglobin",
"    <span class=\"nowrap\">",
"     (g/dL)",
"    </span>",
"    based on the patient age and requirement for respiratory support:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Week 1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With respiratory support &ndash; 11.5",
"     </li>",
"     <li>",
"      No respiratory support &ndash; 10.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Week 2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With respiratory support &ndash; 10.0",
"     </li>",
"     <li>",
"      No respiratory support &ndash; 8.5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Week 3",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With respiratory support &ndash; 8.5",
"     </li>",
"     <li>",
"      No respiratory support &ndash; 7.5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2012 meta-analysis that included two additional trials that did not meet inclusion criteria for the above study reported similar findings of no difference in mortality rates between high and low threshold transfusion groups [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developed countries, the number of transfusions given to neonates has decreased from an average of seven transfusions in the late 1980s down to two transfusions per infant in 2009 during their initial birth hospitalization due to a more restrictive approach to transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Despite this decrease, the majority of ELBW infants still require blood transfusions based upon current protocols. For example, in the above meta-analysis, only 11 percent of infants in the low threshold group and 9 percent in the high threshold group received no transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/12\">",
"     12",
"    </a>",
"    ]. As noted above, most of the patients in this systemic review did not receive erythropoietin. For comparison, only 62 percent of preterm infants &le;800 grams birth weight enrolled in a randomized trial of erythropoietin, iron, folate, and B12 administration required transfusion, compared with 95 percent of the infants not receiving erythropoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Search for other transfusion markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hematocrit and hemoglobin have primarily been the triggers to indicate when transfusion is indicated in neonates, they are not adequate measures. This is illustrated by the observation that some infants remain asymptomatic at a given low hematocrit (hemoglobin), while others are symptomatic (tachycardia, poor weight gain, increased requirement of supplemental oxygen, or increased frequency of apnea or bradycardia) at a similar or higher concentration.",
"   </p>",
"   <p>",
"    Research efforts have focused on identifying a more accurate indicator for transfusions; however, a reliable and sensitive marker has yet to be identified. Investigations to test a more accurate marker for transfusion have included studies of direct or indirect oxygen delivery (eg, peripheral fractional oxygen extraction and oxygen consumption) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], echocardiographic changes in cardiovascular circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], and the use of biochemical markers, such as serum lactate or vascular endothelial growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the currently available data, the following transfusion guidelines have been adopted in several NICUs, = including our own (",
"    <a class=\"graphic graphic_table graphicRef73361 \" href=\"UTD.htm?34/23/35196\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute blood loss that is greater than 20 percent of blood volume.",
"     </li>",
"     <li>",
"      Acute blood loss that is greater than 10 percent of blood volume with symptoms of decreased oxygen delivery, such as persistent acidosis after volume resuscitation.",
"     </li>",
"     <li>",
"      Transfusion should be given to any infant regardless of gestational age if there is an immediate need for increased oxygen delivery that cannot be met with increased respiratory support.",
"     </li>",
"     <li>",
"      The following guidelines for infants with chronic anemia suggest that transfusions should be considered based upon the respiratory support need by the infant. They are dependent upon a hematocrit (hemoglobin) value that is preferably measured from either a central venous or arterial sample. These hemoglobin values are based on a restrictive hemoglobin transfusion threshold and are consistent with the recommendations outlined by the previously discussed meta-analysis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Target hemoglobin or hematocrit'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If a heelstick specimen is used, it should be obtained after adequate warming of the heel. The final decision for a transfusion is at the discretion of the neonatology team.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For infants requiring moderate or significant mechanical ventilation, defined as fraction of inspired oxygen (FiO2) &gt;0.4, and mean airway pressure (MAP) &gt;8 cm H2O on a conventional ventilator or MAP &gt;14 on a high frequency ventilator, the hematocrit trigger is &lt;30 percent (hemoglobin &le;10",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"     </li>",
"     <li>",
"      For infants requiring minimal mechanical ventilation, defined as fraction of inspired oxygen (FiO2) &lt;0.4, and mean airway pressure (MAP) &le;8 cm H2O on a conventional ventilator or MAP &le;14 on a high frequency ventilator, the hematocrit trigger is &lt;25 percent (hemoglobin &le;8",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"     </li>",
"     <li>",
"      The hematocrit trigger is &lt;25 percent (hemoglobin &le;8",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      for infants requiring supplemental oxygen but not mechanical ventilation and one of or more of the following; tachycardia (heart rate &ge;180 beats per minute) for &ge;24 hours, tachypnea (respiratory rate &ge; 60 breaths per minute) for &ge;24 hours, doubling of oxygen requirement from the previous 48 hours, metabolic acidosis as indicated by a pH 7.20 or serum lactate &ge;2.5",
"      <span class=\"nowrap\">",
"       mEq/L,",
"      </span>",
"      weight gain &lt;10",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day over the previous 4 days while receiving &ge;120",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      per day, or if the infant undergoes major surgery within 72 hours. For infants requiring oxygen without any symptoms, a transfusion is not considered until symptoms occur.",
"     </li>",
"     <li>",
"      In asymptomatic infants, the hematocrit trigger is less than 18 percent (hemoglobin &le;6",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      with an absolute reticulocyte",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL",
"      </span>",
"      (&lt;2 percent). Infants without symptoms or oxygen requirements who are actively producing new red cells and have an elevated reticulocyte count likely do not require a red cell transfusion. This last threshold for transfusion is similar to criteria published in 2002 by the Canadian Paediatric Society. In their guideline, criteria for transfusion were for a symptomatic infant with a \"hemoglobin falling below 6",
"      <span class=\"nowrap\">",
"       gm/dL",
"      </span>",
"      with an absolute reticulocyte count less than 100,000 to",
"      <span class=\"nowrap\">",
"       150,000/microL,",
"      </span>",
"      which suggests low plasma concentration of erythropoietin [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other centers have transfusion guidelines with higher hematocrit (hemoglobin) triggers, which are based upon similar requirements for respiratory support [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SELECTION OF RED BLOOD CELL PRODUCTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the decision to transfuse red blood cells (RBCs) has been made, the appropriate RBC product is chosen based upon the clinical setting. Donated whole blood used for transfusion may be modified in several ways that remove varying proportions of non-red cell components. These modifications are particularly important in the neonate because of their increased vulnerability to certain infections, such as cytomegalovirus, potential increased risk of graft versus host disease due to transfusion, and the possibility of alloimmune hemolytic disease of the newborn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Products for acute blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of acute blood loss, especially in life-threatening circumstances, any available RBC product that is compatible with the infant's blood type can be administered. If O negative packed RBCs (PRBCs) are available in the delivery room as an emergency transfusion for the mother, this blood also can be used in the neonate. O negative PRBCs are preferred over O negative whole blood, as the latter contains antibodies directed against A or B blood group, and against leukocytes. O negative whole blood should only be used as a last resort in critically ill neonates. In a sick infant cared for in the NICU, PRBCs are an alternative in an emergency situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hemolytic disease of the newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloimmune hemolytic disease of the newborn (HDN) is a condition in which the red cells of the fetus or newborn are destroyed by maternally derived alloantibodies. These antibodies arise in the mother as the direct result of a blood group incompatibility between the mother and fetus. Infants often require exchange transfusion to remove the maternal alloantibodies, reduce the rate of hemolysis, and prevent significant hyperbilirubinemia. In some cases, a simple transfusion is administered because an exchange transfusion cannot be done in a timely manner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link&amp;anchor=H9#H9\">",
"     \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The different types of HDN include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rh(D) &ndash; The most significant setup for HDN occurs in the Rh-positive infant (ie, D antigen positive) of an Rh-negative mother who has become sensitized and has produced Rh(D) antibodies. An infant who needs either simple transfusion or exchange transfusion because of HDN should receive Rh(D)-negative red cells of the appropriate ABO type.",
"     </li>",
"     <li>",
"      ABO incompatibility &ndash; Humans have four major blood groups in the ABO system (A, B, AB, and O) named for the antigen(s) on the red cell. The ABO system may cause HDN, although most cases are less severe than that caused by the Rh system. In infants with HDN due to ABO incompatibility, donor O cells are washed to remove any plasma that contains alloantibodies. These cells may be suspended in plasma that is compatible with both the infant's red cells and the transfused (donor) cells. AB plasma is compatible in all cases, since it does not contain anti-A or anti-B alloantibodies.",
"     </li>",
"     <li>",
"      Other Rh antibodies &ndash; Other antibodies including Rh antibodies in the C and E systems, and Kell antibodies can cause HDN or acute or delayed hemolytic transfusion reaction. In these cases, red cells that are negative for the antigen, against which the antibody is directed, are used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Packed red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Packed RBCs are the blood products of choice for replacement during surgery, red blood cell loss, and sporadic transfusion therapy. The hematocrit of the unit varies depending upon the preservative solution. In the United States, commonly used solutions include CPDA-1 (citrate, phosphate, dextrose, adenine) with a Hct of 65 to 70 percent, and nutrient preparations, such as Adsol&trade; (AS-1; adenine, glucose,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    , and sodium chloride) and Nutricel&trade; (AS-2; citrate, phosphate, glucose, adenine, and sodium chloride), with a Hct of 50 to 60 percent. RBCs in the nutrient solutions (AS-1 and AS-2) can be used for 42 days after collection and those preserved in CPDA-1 for more than 28 days [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that the use of fresh red blood cell (RBC) transfusions in preterm infants would result in lower rates of organ dysfunction, nosocomial infection, and length of stay. However, a Canadian multi-center trial of premature infants (birth weight less than 1250 g) demonstrated no benefit in the use of fresh RBC (stored for 7 days or less) transfusion compared with transfusions using RBCs stored under current standard blood bank practice [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/33\">",
"     33",
"    </a>",
"    ]. Specifically, there was no difference in the primary composite outcome of major neonatal morbidities that included necrotizing enterocolitis, retinopathy of prematurity, bronchopulmonary dysplasia, and intraventricular hemorrhage between groups of infants who received fresh RBCs (mean age of RBCs, 5.1 &plusmn; 2.1 days) and those administered standard transfusions (mean age of RBCs, 14.6 &plusmn; 8.3 days). Infants in the fresh RBC group were exposed to a greater mean number of donors compared with the standard RBC group (3.7 &plusmn; 2.7 donors versus 2.1 &plusmn; 1.6 donors). These findings show that no alteration for the current standard RBCs storage time practices is needed for preterm infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Leukoreduced and irradiated red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukoreduction filters remove approximately 99.9 percent of white blood cells from PRBCs, which reduces febrile non-hemolytic transfusion reactions, prevents alloimmunization, and reduces (but does not completely prevent) the transmission of certain infections (notably cytomegalovirus [CMV]). However, leukoreduction does not eliminate all lymphocytes and cannot prevent transfusion-associated-graft-versus-host disease (TA-GVHD).",
"   </p>",
"   <p>",
"    Irradiation prevents TA-GVHD in susceptible recipients. The dose of radiation is not sufficient to kill viruses and irradiation does not provide a CMV-safe product.",
"   </p>",
"   <p>",
"    Leukoreduced PRBCs should be used in all neonates. In addition, most blood banks will also irradiate leukoreduced PRBCs prior to neonatal transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     CMV-safe red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV-safe products (including CMV-seronegative and leukoreduced red cells) reduce the transmission of CMV in seronegative recipients. CMV-seronegative PRBCs should be used in the following populations, although many NICUs use CMV-seronegative PRBCs in all neonates:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infants awaiting or undergoing transplantation",
"     </li>",
"     <li>",
"      Immunocompromised infants",
"     </li>",
"     <li>",
"      Preterm infants of CMV seronegative mothers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cord blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cord blood has been suggested as a form of \"autologous\" blood donation, most birthing institutions are not prepared for the collection and storage of neonatal cord blood. Even with a program that collects and processes umbilical cord blood, autologous blood was only available in one-third of neonates that required transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative to cord blood collection that may reduce erythrocyte transfusions is delayed clamping of the umbilical cord, especially in preterm infants. A 30 second delay in clamping promotes a placental blood transfer of 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/35\">",
"     35",
"    </a>",
"    ]. In preterm infants, late compared with early cord clamping is associated with a significantly higher hematocrit four hours after birth, fewer transfusions for anemia or low blood pressure, less likelihood of IVH, and no increase in the need for treatment of jaundice. The effect of delayed umbilical cord clamping is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link&amp;anchor=H30#H30\">",
"     \"Management of normal labor and delivery\", section on 'Cord clamping'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link&amp;anchor=H31#H31\">",
"     \"Management of normal labor and delivery\", section on 'Cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume of transfusion is dependent upon the desired rise in hematocrit.",
"   </p>",
"   <p>",
"    The volume of transfusion in mL is equal to the following calculation:",
"   </p>",
"   <p>",
"    Wt (kg) X blood volume per kg X (Desired Hct - Observed",
"    <span class=\"nowrap\">",
"     Hct)/Hct",
"    </span>",
"    PRBCs",
"   </p>",
"   <p>",
"    In the newborn, the blood volume is about 90",
"    <span class=\"nowrap\">",
"     cc/kg.",
"    </span>",
"    Transfusions generally are given as packed red blood cells (PRBCs), in aliquots of 10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    over two to four hours. In some circumstances, such as hemodynamic instability or hypovolemia due to blood loss, a smaller volume (10",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    is given more rapidly (over one to two hours). Data are inconclusive regarding the optimal volume for neonatal PRBC transfusion. In a systematic review of the literature, there were only four trials with 146 infants that compared transfusion volumes of 10 versus 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/14\">",
"     14",
"    </a>",
"    ]. Although there were no reports of difference in neonatal outcomes including mortality, the number of patients is too small to reach any definitive conclusion regarding aliquot choice for PRBC transfusion.",
"   </p>",
"   <p>",
"    In ELBW and VLBW infants, the small volumes, which may be as low as 7 mL of blood for a single transfusion, require the use of special equipment to maximize the use of a single unit from a donor. In addition, these systems allow for serial transfusions to an individual neonate from the same donor.",
"   </p>",
"   <p>",
"    These include the following two systems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small bags may come as part of a transfusion set (referred to as satellite packs) in which four or six aliquots can be made from a single red cell unit. If the blood bank has a sterile connecting device, the small bags can be connected to the large blood unit, and an appropriate amount withdrawn at any time.",
"     </li>",
"     <li>",
"      Another convenient device for small-volume transfusions is a syringe set in which the syringe is sterilely connected to the original unit. Blood is drawn through a filter into a syringe, and can be used within four hours without further filtration. Such systems have been shown to be safe [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/36\">",
"       36",
"      </a>",
"      ] and can increase the numbers of transfusions from a single unit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With both systems, the original expiration date of the unit is maintained if the sampling device remains connected to the original unit in a sterile manner. This period may be up to six weeks for use of a single unit in a nutrient solution such as Adsol&trade; (AS-1) and Nutricel&trade; (AS-2). If a single unit is designated for a premature infant and is used until its expiration date, as many as 13 individual transfusions can be made from a single donor unit, which markedly decreases donor exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9048/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia occurs when the red blood cell mass does not adequately meet the oxygen demands of the tissue. Neonates may require red blood cell (RBCs) transfusions because of significant anemia due to acute blood loss or chronic anemia due to physiologic anemia and blood loss from phlebotomy. In particular, anemia in preterm infants (referred to as anemia of prematurity) is more severe and presents earlier in life.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates with significant acute blood loss require immediate fluid resuscitation. Indications for RBC transfusion in a neonate with acute blood loss following volume resuscitation include persistent acidosis indicating inadequate oxygen delivery, ongoing bleeding, and a blood loss greater than 20 percent of the infant's blood volume.",
"     </li>",
"     <li>",
"      In the acute setting of blood loss, especially in life-threatening circumstances, any available RBC product that is compatible with the infant's blood type can be administered. O negative packed RBCs (PRBCs) are preferred over O negative whole blood, as the latter contains antibodies directed against A or B blood group, and leukocytes. O negative whole blood should only be used as a last resort in critically ill neonates. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute blood loss'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Products for acute blood loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Target hemoglobin and hematocrit have been used universally as clinical indicators for RBC transfusion in neonates due to chronic anemia. Over the past three decades, clinical practice progressed from using high trigger levels (hematocrit of 40 percent referred to as a \"liberal\" approach) to lower levels (a \"restrictive\" approach). Based on the available data, it appears that a restrictive approach results in fewer transfusions and does not increase the risk of death or serious morbidity. In our practice, we use a restrictive approach for neonatal transfusions that is based upon hematocrit triggers and the respiratory support required by the infant (",
"      <a class=\"graphic graphic_table graphicRef73361 \" href=\"UTD.htm?34/23/35196\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Target hemoglobin or hematocrit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood products for neonates with hemolytic disease of the newborn (HDN) who require either exchange or simple transfusion need to be compatible with the infant's blood type. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hemolytic disease of the newborn'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leukoreduced PRBCs should be used in all neonatal transfusions because it reduces febrile non-hemolytic transfusion reactions, prevents alloimmunization, and reduces the transmission of certain infections (notably cytomegalovirus [CMV]). Most neonatal intensive care units also use irradiated RBCs, which do not provide a CMV-safe product but prevent transfusion-associated-graft-versus-host disease.",
"     </li>",
"     <li>",
"      CMV-seronegative PRBCs are reserved for immunodeficient neonates, those who are awaiting transplantation, and preterm infants of seronegative mothers. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Packed red cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the neonate, small volumes, which may be as low as 7 mL of blood for a single transfusion in extremely low birth weight infants (birth weight &lt;1000 g), require the use of special equipment that allows several aliquots to be administered from a single unit. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/1\">",
"      Blau J, Calo JM, Dozor D, et al. Transfusion-related acute gut injury: necrotizing enterocolitis in very low birth weight neonates after packed red blood cell transfusion. J Pediatr 2011; 158:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/2\">",
"      Baer VL, Lambert DK, Henry E, et al. Among very-low-birth-weight neonates is red blood cell transfusion an independent risk factor for subsequently developing a severe intraventricular hemorrhage? Transfusion 2011; 51:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/3\">",
"      dos Santos AM, Guinsburg R, de Almeida MF, et al. Red blood cell transfusions are independently associated with intra-hospital mortality in very low birth weight preterm infants. J Pediatr 2011; 159:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/4\">",
"      Baer VL, Lambert DK, Henry E, et al. Red blood cell transfusion of preterm neonates with a Grade 1 intraventricular hemorrhage is associated with extension to a Grade 3 or 4 hemorrhage. Transfusion 2011; 51:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/5\">",
"      Rashid N, Al-Sufayan F, Seshia MM, Baier RJ. Post transfusion lung injury in the neonatal population. J Perinatol 2013; 33:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/6\">",
"      Shannon KM, Keith JF 3rd, Mentzer WC, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 1995; 95:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/7\">",
"      Bifano EM. The effect of hematocrit (HCT) level on clinical outcomes in Extremely Low Birthweight (ELBW) infants. Pediatric Research 2001; 49:311A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/8\">",
"      Bell EF, Strauss RG, Widness JA, et al. Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. Pediatrics 2005; 115:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/9\">",
"      Kirpalani H, Whyte RK, Andersen C, et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr 2006; 149:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/10\">",
"      Chen HL, Tseng HI, Lu CC, et al. Effect of blood transfusions on the outcome of very low body weight preterm infants under two different transfusion criteria. Pediatr Neonatol 2009; 50:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/11\">",
"      Blank JP, Sheagren TG, Vajaria J, et al. The role of RBC transfusion in the premature infant. Am J Dis Child 1984; 138:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/12\">",
"      Whyte R, Kirpalani H. Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants. Cochrane Database Syst Rev 2011; :CD000512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/13\">",
"      Whyte RK, Kirpalani H, Asztalos EV, et al. Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. Pediatrics 2009; 123:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/14\">",
"      Venkatesh V, Khan R, Curley A, et al. The safety and efficacy of red cell transfusions in neonates: a systematic review of randomized controlled trials. Br J Haematol 2012; 158:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/15\">",
"      Widness JA, Seward VJ, Kromer IJ, et al. Changing patterns of red blood cell transfusion in very low birth weight infants. J Pediatr 1996; 129:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/16\">",
"      Maier RF, Sonntag J, Walka MM, et al. Changing practices of red blood cell transfusions in infants with birth weights less than 1000 g. J Pediatr 2000; 136:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/17\">",
"      Haiden N, Schwindt J, Cardona F, et al. Effects of a combined therapy of erythropoietin, iron, folate, and vitamin B12 on the transfusion requirements of extremely low birth weight infants. Pediatrics 2006; 118:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/18\">",
"      Alverson DC. The physiologic impact of anemia in the neonate. Clin Perinatol 1995; 22:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/19\">",
"      Wardle SP, Garr R, Yoxall CW, Weindling AM. A pilot randomised controlled trial of peripheral fractional oxygen extraction to guide blood transfusions in preterm infants. Arch Dis Child Fetal Neonatal Ed 2002; 86:F22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/20\">",
"      Bifano EM, Smith F, Borer J. Relationship between determinants of oxygen delivery and respiratory abnormalities in preterm infants with anemia. J Pediatr 1992; 120:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/21\">",
"      Bard H, Fouron JC, Chessex P, Widness JA. Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity in infants with bronchopulmonary dysplasia. J Pediatr 1998; 132:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/22\">",
"      B&ouml;hler T, Janecke A, Linderkamp O. Blood transfusion in late anemia of prematurity: effect on oxygen consumption, heart rate, and weight gain in otherwise healthy infants. Infusionsther Transfusionsmed 1994; 21:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/23\">",
"      Alkalay AL, Galvis S, Ferry DA, et al. Hemodynamic changes in anemic premature infants: are we allowing the hematocrits to fall too low? Pediatrics 2003; 112:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/24\">",
"      Izraeli S, Ben-Sira L, Harell D, et al. Lactic acid as a predictor for erythrocyte transfusion in healthy preterm infants with anemia of prematurity. J Pediatr 1993; 122:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/25\">",
"      Tschirch E, Weber B, Koehne P, et al. Vascular endothelial growth factor as marker for tissue hypoxia and transfusion need in anemic infants: a prospective clinical study. Pediatrics 2009; 123:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/26\">",
"      Arifuzzaman M, Oshima T, Nakade S, Mori H. Characterization of HscC (Hsc62), homologue of Hsp70 in Escherichia coli: over-expression of HscC modulates the activity of house keeping sigma factor sigma70. Genes Cells 2002; 7:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/27\">",
"      Bell EF. When to transfuse preterm babies. Arch Dis Child Fetal Neonatal Ed 2008; 93:F469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/28\">",
"      Strauss RG. How I transfuse red blood cells and platelets to infants with the anemia and thrombocytopenia of prematurity. Transfusion 2008; 48:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/29\">",
"      Venkatesh V, Khan R, Curley A, et al. How we decide when a neonate needs a transfusion. Br J Haematol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     Menitove JE. Standards for blood banks and transfusion services, 21st ed, American Association of Blood Banks, Bethesda 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/31\">",
"      Strauss RG, Burmeister LF, Johnson K, et al. Feasibility and safety of AS-3 red blood cells for neonatal transfusions. J Pediatr 2000; 136:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/32\">",
"      Fernandes da Cunha DH, Nunes Dos Santos AM, Kopelman BI, et al. Transfusions of CPDA-1 red blood cells stored for up to 28 days decrease donor exposures in very low-birth-weight premature infants. Transfus Med 2005; 15:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/33\">",
"      Fergusson DA, H&eacute;bert P, Hogan DL, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA 2012; 308:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/34\">",
"      Khodabux CM, von Lindern JS, van Hilten JA, et al. A clinical study on the feasibility of autologous cord blood transfusion for anemia of prematurity. Transfusion 2008; 48:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/35\">",
"      Aladangady N, McHugh S, Aitchison TC, et al. Infants' blood volume in a controlled trial of placental transfusion at preterm delivery. Pediatrics 2006; 117:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/36\">",
"      Chambers LA. Evaluation of a filter-syringe set for preparation of packed cell aliquots for neonatal transfusion. Am J Clin Pathol 1995; 104:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9048/abstract/37\">",
"      Strauss RG, Burmeister LF, Johnson K, et al. AS-1 red cells for neonatal transfusions: a randomized trial assessing donor exposure and safety. Transfusion 1996; 36:873.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5041 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9048=[""].join("\n");
var outline_f8_53_9048=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17001196\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Target hemoglobin or hematocrit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Search for other transfusion markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SELECTION OF RED BLOOD CELL PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Products for acute blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hemolytic disease of the newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Packed red cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Leukoreduced and irradiated red cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - CMV-safe red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cord blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5041|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/23/35196\" title=\"table 1\">",
"      Transfusion guidelines for the newborn infant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=related_link\">",
"      Anemia of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=related_link\">",
"      Indications for red blood cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=related_link\">",
"      Pathology and pathogenesis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=related_link\">",
"      Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_53_9049="Treatment of high or very high risk myelodysplastic syndromes";
var content_f8_53_9049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of high or very high risk myelodysplastic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/53/9049/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/53/9049/contributors\">",
"     Elihu H Estey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/53/9049/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/53/9049/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/53/9049/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/53/9049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/53/9049/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/53/9049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H48545776\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndromes (MDS) encompass a series of hematologic conditions characterized by chronic cytopenias (anemia, neutropenia, thrombocytopenia) accompanied by abnormal cellular maturation. As a result, patients with MDS are at risk for symptomatic anemia, infection, and bleeding, as well as progression to acute myeloid leukemia (AML), which is often refractory to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with MDS die because of the consequences of bone marrow failure rather than transformation to AML. Thus, use of terms such as \"pre-leukemia\" or \"smoldering leukemia\" can be misleading if taken to imply that death or morbidity from MDS results only when AML develops. Indeed, the distinction between MDS and AML is itself arbitrary, as patients with 20 to 30 percent blasts are considered to have MDS by French-American-British (FAB) criteria, but AML by the World Health Organization (WHO) classification.",
"   </p>",
"   <p>",
"    For many years, transfusion with packed red blood cells and platelets and the use of erythropoiesis stimulating agents were the only therapy available. More recently, chemotherapy agents directed at the underlying disorder have been developed and continue to be studied for patients with MDS (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ). However, due to the advanced age of most patients, the chronicity of the disease, and its attendant morbidities, supportive care remains a central component of the management of all patients with MDS. Patients should be treated as needed with antibiotics for infection and platelet transfusions for bleeding in the setting of thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link\">",
"     \"Management of the complications of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no consensus regarding a standard treatment approach for patients with symptomatic MDS, and patients should be encouraged to enroll on clinical trials whenever available. Our treatment approach incorporates knowledge of the patient&rsquo;s performance status, the International Prognostic Scoring System (IPSS) (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and revised IPSS (IPSS-R) (",
"    <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"     table 2",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) MDS risk categories, and other disease characteristics (ie, cytopenias present, serum erythropoietin level) to help guide management decisions.",
"   </p>",
"   <p>",
"    This topic review will discuss the management of patients with MDS and a high (&gt;4.5 to 6 points) or very high (&gt;6 points) IPSS-R score. The treatment of patients with an intermediate (&gt;3 to 4.5 points), low (&gt;1.5 to 3 points), or very low (&le;1.5 points) IPSS-R score, the management of the complications of MDS, details on the use of hematopoietic cell transplantation in MDS, and the prognosis of MDS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=see_link\">",
"     \"Hematopoietic cell transplantation in myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48545783\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with MDS require immediate treatment. Immediate treatment is indicated for patients with symptomatic cytopenia (anemia, thrombocytopenia, neutropenia with recurrent infections). Asymptomatic patients may be followed expectantly with serial examinations and laboratory studies. Immunizations should be updated and smoking ceased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H515110#H515110\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Indications for treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H515117#H515117\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Management of asymptomatic MDS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48545797\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to affect treatment options. In addition to a history and physical examination, it is our practice to perform laboratory studies and a unilateral bone marrow aspirate and biopsy in all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H516641#H516641\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48545804\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding a standard treatment approach for patients with symptomatic MDS, and patients should be encouraged to enroll on clinical trials whenever available. Our treatment approach is similar to that proposed by the MDS Panel for Practice Guidelines of the National Comprehensive Cancer Network (NCCN). This approach incorporates knowledge of the patient&rsquo;s performance status, the International Prognostic Scoring System (IPSS) (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and revised IPSS (IPSS-R) MDS risk categories, and other disease characteristics (ie, cytopenias present, serum erythropoietin level) to help guide management decisions. However, despite the increased availability of treatment guidelines, it is important to individualize care for the patient with MDS.",
"   </p>",
"   <p>",
"    Treatment options for patients with MDS typically fall into one of three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive care includes the use of antibiotics for infection and red cell and platelet transfusions in the setting of symptomatic anemia and thrombocytopenia, respectively. Prophylactic antibiotics are generally not helpful and this strategy may select for antibiotic resistance. Supportive care is an important adjunct to the management of",
"      <strong>",
"       all",
"      </strong>",
"      patients with MDS and can be considered as the sole treatment modality for a subset of patients with lower risk MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link\">",
"       \"Management of the complications of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low intensity therapies include hematopoietic growth factors, DNA hypomethylating agents, immunosuppressive therapy, and low intensity chemotherapy. These can be administered in the outpatient setting and have a low risk of treatment-related morbidity and mortality. Low intensity treatments can improve symptoms and quality of life, but are not curative.",
"     </li>",
"     <li>",
"      High intensity therapies include intensive combination chemotherapy and allogeneic hematopoietic cell transplantation (HCT). They require hospitalization and entail significant risk of treatment-related mortality. However, these treatments may improve blood counts more quickly than less intensive therapy, reduce the risk of death from MDS, and may alter the MDS disease course. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=see_link\">",
"       \"Hematopoietic cell transplantation in myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High intensity therapies are generally reserved for patients with high or very high IPSS-R scores. This allows for the avoidance of treatment-related morbidity and mortality in most patients with a relatively good prognosis, and allows for the aggressive treatment of disease in those with a poor prognosis.",
"   </p>",
"   <p>",
"    Of note, there are certain patient populations that require special attention and modification of this approach. As an example, patients with therapy-related MDS have a particularly poor prognosis and are treated in a similar fashion to those with therapy-related acute myeloid leukemia (AML). (See",
"    <a class=\"local\" href=\"#H518259\">",
"     'Special patient populations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48546540\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a high (&gt;4.5 to 6 points) or very high (&gt;6 points) IPSS-R score have an estimated median survival of 8 to 18 months with supportive care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/1\">",
"     1",
"    </a>",
"    ]. Those with a good performance status are primarily treated with intensive chemotherapy or allogeneic hematopoietic cell transplantation (HCT) in an attempt to alter the disease course. In this sense, their treatment is very similar to that for acute myeloid leukemia (AML), with the natural history and response to treatment in high-risk MDS being very close to AML, and with the natural history of high-risk MDS more reminiscent of AML than of lower risk MDS. Indeed the distinction between high-risk MDS and AML is arbitrary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allogeneic HCT is the only treatment for MDS with the potential for cure, but its use has been limited by donor availability and the advanced age of most patients with this disorder. However, the advent of reduced intensity HCT, which relies on a graft-versus-host disease effect and the use of matched unrelated donors has extended the applicability of HCT to patients in their 60s and even early 70s. Such intensive therapies are preferred in this patient group because a low expected median survival and high rate of transformation to acute myeloid leukemia when these patients are treated with supportive care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/2\">",
"     2",
"    </a>",
"    ]. This treatment approach may also be considered for patients with a WHO Prognostic Scoring System (WPSS) score of high or very high risk. Patients with an intermediate risk IPSS-R score may be treated with this approach or with those used for higher risk MDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link&amp;anchor=H861596#H861596\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\", section on 'WHO prognostic scoring system (WPSS)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=see_link&amp;anchor=H18#H18\">",
"     \"Hematopoietic cell transplantation in myelodysplastic syndromes\", section on 'Nonmyeloablative or reduced intensity regimens'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17341143\">",
"     'Intermediate risk IPSS-R'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As such, our choice of preferred therapy depends largely upon the patient&rsquo;s candidacy for allogeneic hematopoietic cell transplantation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with high or very high IPSS-R risk scores who are eligible for allogeneic HCT and have an available related or unrelated matched donor, we recommend high intensity chemotherapy followed by allogeneic hematopoietic transplantation. If a donor is not available, these patients may be treated with intensive induction therapy alone such as that used for acute myeloid leukemia (AML) or with a DNA hypomethylating agent with plans to treat with intensive induction therapy at the time of AML transformation. (See",
"      <a class=\"local\" href=\"#H48546547\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with high or very high IPSS-R risk scores who are not eligible for allogeneic HCT, we suggest entry into a clinical trial. Alternatively, a DNA hypomethylating agent may be offered to a patient who is fully informed of the relatively modest survival advantage associated with the use of these agents and nonetheless prefers the use of these drugs to the uncertainty of a clinical trial. (See",
"      <a class=\"local\" href=\"#H48546561\">",
"       'DNA hypomethylating agents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Supportive care is an important adjunct to the management of",
"      <strong>",
"       all",
"      </strong>",
"      patients with MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link\">",
"       \"Management of the complications of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48546547\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High intensity chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) in MDS has been limited by donor availability and the advanced age of most patients with this disorder. Following improvements in technique and supportive care and the introduction of reduced intensity conditioning regimens, the upper age limit for allogeneic HCT has been increased to 70 years. In addition, it seems likely that results with matched unrelated donor transplants are similar to those seen with matched sibling transplants, further extending the applicability of allogeneic HCT in MDS. Nonetheless, allogeneic HCT is still not an option for many patients with MDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=see_link\">",
"     \"Hematopoietic cell transplantation in myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allogeneic HCT should be considered for patients with MDS who are &lt;70 years old and have an estimated survival sufficiently short as to balance the risks associated with allogeneic HCT. The decision to pursue HCT depends upon a number of criteria, including the IPSS score (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ) and risk of disease progression, with particular reference to underlying infections and the overall health of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using decision analysis and prospectively collected registry data, and in the absence of data from randomized trials, the following recommendations have been made concerning the timing of allogeneic HCT in patients with MDS as classified by the original IPSS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in the low and intermediate-1 IPSS risk groups, delayed transplantation is associated with maximum discounted and quality-adjusted discounted life years. The optimal timing for transplantation is at the time of the development of a new cytogenetic abnormality, appearance of a clinically important cytopenia, or the progression to a higher risk IPSS group.",
"     </li>",
"     <li>",
"      For patients with intermediate-2 and high IPSS risk scores, who have poor survival irrespective of their age, transplantation at the time of diagnosis is associated with maximization of discounted life years for the entire cohort of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the effectiveness of allogeneic HCT in younger patients with MDS, attempts have been made both to increase the safety of the procedure and to find donors other than HLA-matched siblings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of reduced-intensity allogeneic HCT relies on a graft-versus-tumor effect and permits HCT to be performed in patients up to 70 to 75 years of age, or in younger patients with co-morbid conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"       \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is increasing use of matched unrelated donor (MUD) transplants, which may be as effective as HLA-matched sibling transplants. However, use of more restrictive matching criteria means that fewer patients will find donors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"       \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with all reports of new treatments, attention must be given to the possibility that patients receiving these treatments represent only a small, unrepresentative subset of patients with MDS. The use of allogeneic HCT for the treatment of MDS is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=see_link\">",
"     \"Hematopoietic cell transplantation in myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48546554\">",
"    <span class=\"h2\">",
"     High intensity chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive induction chemotherapy such as that used for de novo AML has generally not been as effective in patients with MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. This likely reflects the older age of patients with MDS, the stem cell nature of the disease, and the presence of poor risk cytogenetics, rather than a specific unfavorable effect due to MDS per se. Patients with MDS and &gt;10 percent bone marrow blasts should be considered for AML induction chemotherapy if they are relatively young (ie, age &lt;60 years), with a good performance status and good risk cytogenetics [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H26#H26\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Post-remission treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of acute myeloid leukemia in older adults\", section on 'Selection of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multicenter study explored the effect of AML induction chemotherapy followed by allogeneic or autologous hematopoietic cell transplantation in 184 evaluable patients with MDS or secondary AML (AML-MDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/13\">",
"     13",
"    </a>",
"    ]. Eligible patients were &lt;60 years of age (median age 47) with a good performance status; most had intermediate-2 or high risk MDS (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ), or AML-MDS. The complete remission rate following one or two courses of induction therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    was 54 percent, with 15 percent dying during remission induction therapy. Ninety of the 100 patients achieving CR underwent consolidation therapy with intermediate-dose cytarabine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    , and 61 received the planned allogeneic or autologous transplant.",
"   </p>",
"   <p>",
"    At a median follow-up of 3.6 years, median survival was 13 months, with an actuarial survival at four years of 26 percent. This compares favorably with four-year survival rates of 10 and zero percent in the original IPSS study of patients with intermediate-2 and high risk disease, respectively, who were treated with supportive care or nonintensive treatment approaches only (",
"    <a class=\"graphic graphic_table graphicRef66149 \" href=\"UTD.htm?14/5/14427\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63397 \" href=\"UTD.htm?1/9/1183\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link&amp;anchor=H2102498#H2102498\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\", section on 'International prognostic scoring systems (IPSS and IPSS-R)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48546561\">",
"    <span class=\"h2\">",
"     DNA hypomethylating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two DNA hypomethylating agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    ) have been approved by the US Food and Drug Administration for use in patients with MDS. While each has demonstrated superior response rates and a longer time to AML transformation when compared with placebo, they have not been directly compared with one another in a randomized trial. Results from these trials have not been reported using the IPSS-R prognostic groups. These agents are our preferred therapy for most patients with symptomatic lower risk MDS. While more intensive therapies are preferred for patients with higher IPSS scores, DNA hypomethylating agents are commonly used for the treatment of patients with higher risk scores who are not eligible for intensive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2447218#H2447218\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'DNA hypomethylating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective phase III study (AZA-001) randomly assigned therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for seven days every 28 days) or a &ldquo;conventional care regimen&rdquo; (ie, best supportive care, low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , or AML induction chemotherapy as selected by the investigators before randomization) in 358 patients with higher-risk MDS (ie, RAEB, RAEB-T, or CMML with an IPSS score of Int-2 or high risk) (",
"      <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/14\">",
"       14",
"      </a>",
"      ]. Of patients selected by their physicians to be candidates for best supportive care alone, low-dose cytarabine, or AML induction therapy, 145, 45, and 17 patients were randomly assigned to azacitidine, respectively. At a median follow-up of 21 months, when compared with the conventional care regimens, treatment with azacitidine resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Significantly better median overall survival (24.5 versus 15 months; hazard ratio for survival 0.58; 95% CI 0.43-0.77)",
"     </li>",
"     <li>",
"      Significantly better two-year survival rates (51 versus 26 percent)",
"     </li>",
"     <li>",
"      Less toxicity (eg, grade 3 to 4 cytopenias and length of hospitalization) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The survival benefit for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      was seen across all prognostic subgroups analyzed, including those with poor, intermediate, and good cytogenetics according to the IPSS, as well as those &ge;75 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/16\">",
"       16",
"      </a>",
"      ]. A better response to azacitidine has also been reported in subjects with trisomy 8 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As part of a compassionate use program, 282 patients with higher-risk MDS were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      given for a median of six cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. A complete or partial response was seen in 17 percent and clinical hematologic improvement was seen in an additional 21 percent. The median overall survival was 13.5 months and the estimated three-year survival rate was 17 percent. Markers of good outcome were validated in a separate cohort and included a performance status &lt;2, no circulating blasts, red blood cell transfusion requirement &lt;4 units over an eight-week period, and a good IPSS cytogenetic risk group. Patients who met all of these criteria had a median survival of 32 months.",
"     </li>",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       EORTC/German",
"      </span>",
"      MDS trial randomly assigned 233 patients with MDS (93 percent intermediate-2 or high IPSS) to best supportive care with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/21\">",
"       21",
"      </a>",
"      ]. At a median follow-up of 2.5 years, median overall survival was 8.5 months for BSC versus 10.1 months for decitabine, a difference that was not statistically significant. Decitabine therapy was associated with higher response rates and improvement in patient-reported quality of life measures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results of these studies suggest that treatment with a DNA hypomethylating agent should be considered in select higher-risk patients with MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. A crucial question is whether the above-noted improvement in survival with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    is sufficient to consider it the preferred option in these patients. The answer to this question is likely patient- and physician-dependent, and it is crucial that patients be informed of the relatively modest survival advantage associated with use of azacitidine, compared with what would be expected if the patient did not have high-risk MDS.",
"   </p>",
"   <p>",
"    The shorter median survival in the best supportive care-only groups in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    (8.5 months) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    (12 months) randomized trials described above suggests that the two study populations were different, although both were nominally \"high risk&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/14,26\">",
"     14,26",
"    </a>",
"    ]. It is also possible that decitabine was not given long enough (40 percent received only two cycles) or at the optimal dose or inter-cycle interval (the dose was 15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every eight hours for three days every six weeks). It is noteworthy that the difference in median survival between azacitidine as given in the randomized study (24.5 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/15\">",
"     15",
"    </a>",
"    ]) and as given in the compassionate use program (13.5 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/19\">",
"     19",
"    </a>",
"    ]) is larger than the difference between the &ldquo;conventional care regimen&rdquo; and azacitidine in the randomized study, indicating the powerful role patient selection plays in results of even randomized trials.",
"   </p>",
"   <p>",
"    Given the prospective trials demonstrating a potential benefit with each of these agents and the lack of a randomized trial comparing these agents to one another, either agent may be used. Some clinicians prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    because it is given intravenously over fewer days. Other clinicians prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    because it can be administered subcutaneously as an outpatient and requires less time in an infusion center. Additional details regarding the administration of these agents are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2446335#H2446335\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Azacitidine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2446356#H2446356\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Decitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518259\">",
"    <span class=\"h1\">",
"     SPECIAL PATIENT POPULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of MDS in most patients can be guided by the treatment strategy outlined above. However, there are certain patient populations that require special attention and modification of this approach. These patient populations are described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17341143\">",
"    <span class=\"h2\">",
"     Intermediate risk IPSS-R",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for patients with an intermediate risk (&gt;3 to 4.5 points) IPSS-R score include those used for patients with low or very low risk IPSS-R scores and the more intensive therapies typically used for patients with high or very high risk IPSS-R scores. A choice among these treatments must take into consideration the patient&rsquo;s values and preferences, and their interpretation of what constitutes a reasonable survival and reasonable risk. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H17341115#H17341115\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Intermediate risk IPSS-R'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48547460\">",
"    <span class=\"h2\">",
"     Therapy-related MDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons who are exposed to cytotoxic agents are at risk of developing acute myeloid leukemia (t-AML), myelodysplastic syndrome (t-MDS), and myelodysplastic",
"    <span class=\"nowrap\">",
"     syndrome/myeloproliferative",
"    </span>",
"    neoplasms",
"    <span class=\"nowrap\">",
"     (t-MDS/MPN).",
"    </span>",
"    These conditions lie along a continuum of disease and are categorized by the 2008 WHO classification system as therapy-related myeloid neoplasms (t-MN) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/27\">",
"     27",
"    </a>",
"    ]. This is a heterogeneous and poorly defined group of patients who have a shorter median survival than patients with de novo AML, MDS, or",
"    <span class=\"nowrap\">",
"     MDS/MPN.",
"    </span>",
"    The treatment of t-MDS is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48547467\">",
"    <span class=\"h2\">",
"     Patients with 5q deletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with low or intermediate-1 risk MDS characterized by del(5q) with or without other cytogenetic abnormalities have demonstrated high response rates to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2443602#H2443602\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Patients with 5q deletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    has been less effective in those with higher risk MDS. This was shown in a phase II trial of lenalidomide (10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally) in 47 patients, of whom 60 and 40 percent were intermediate-2 or high risk, respectively. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematologic response was noted in 13 patients (27 percent), including seven complete hematologic remissions (15 percent).",
"     </li>",
"     <li>",
"      Six of nine patients with isolated del 5q achieved complete remission versus one of 11 with one additional chromosomal abnormality and none of those with more than one additional abnormality.",
"     </li>",
"     <li>",
"      Complete remissions were obtained in 35 percent of those with initial platelet counts",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL",
"      </span>",
"      versus none of the 27 with platelet counts",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL.",
"      </span>",
"     </li>",
"     <li>",
"      Survival was relatively short (median nine months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with intermediate-2 or high risk MDS with or without del(5q), we suggest high intensity therapy. (See",
"    <a class=\"local\" href=\"#H48546540\">",
"     'Choice of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8347533\">",
"    <span class=\"h2\">",
"     Chronic myelomonocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myelomonocytic leukemia (CMML) is considered by the WHO to have elements of both a myelodysplastic as well as a myeloproliferative nature. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2444494#H2444494\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Chronic myelomonocytic leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48547509\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are followed longitudinally to assess disease response to therapy and to monitor for disease progression. Standardized response criteria have been developed that use bone marrow and peripheral blood analysis to allow better comparisons between published studies and to help guide treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H515592#H515592\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Patient follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48548443\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT OR REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a general lack of effective treatments for the management of recurrent or refractory MDS and patients should be encouraged to participate in clinical trials, whenever available.",
"   </p>",
"   <p>",
"    Outside of a clinical trial, the management of patients with recurrent or refractory MDS is largely dependent upon the patient&rsquo;s prior therapy. Patients who have not yet been treated with DNA hypomethylating agents (ie, those initially treated with transplantation or immunosuppressive therapy) may be offered a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    . There is a paucity of data regarding the use of a DNA hypomethylating agent after the failure of another DNA hypomethylating agent (eg, the use of decitabine after failure of azacitidine or vice versa).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48548464\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ). For interested patients, relatives, and physicians, the Aplastic Anemia and MDS International Foundation maintains a website (",
"    <a class=\"external\" href=\"file://www.aamds.org/\">",
"     www.aamds.org",
"    </a>",
"    ), which contains additional information as well as a listing of clinical trials in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H515621#H515621\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials may be particularly attractive for particular patient populations known to have a worse prognosis. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have attained a complete remission but still have evidence of minimal residual disease (MRD) are more likely to relapse after transplantation than those without MRD at the time of transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?8/53/9049/abstract/30\">",
"       30",
"      </a>",
"      ]. Such patients may choose to enroll on a clinical trial even if they will undergo transplant subsequently.",
"     </li>",
"     <li>",
"      Although treatment with DNA hypomethylating agents undoubtedly prolongs survival, the degree of prolongation is modest (8 to 10 months) when compared with the life expectancy of age-matched healthy adults. Knowing the results of therapy with these agents, some patients would prefer entry onto a clinical trial in the hope that it would yield longer survival even after being made aware that the trial&rsquo;s results might ultimately prove worse than those with DNA hypomethylating agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       \"Patient information: Bone marrow transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48548729\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no agreed upon standard treatment approach for patients with symptomatic myelodysplastic syndrome (MDS) and patients should be encouraged to enroll in clinical trials whenever available. Our treatment approach incorporates knowledge of the patient&rsquo;s performance status, the revised International Prognostic Scoring System (IPSS-R) MDS risk category (",
"      <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=see_link\">",
"       calculator 2",
"      </a>",
"      ), to help guide management decisions. (See",
"      <a class=\"local\" href=\"#H48546540\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate treatment is indicated for patients with symptomatic cytopenia (anemia, thrombocytopenia, neutropenia with recurrent infections). Asymptomatic patients may be followed expectantly with serial examinations and laboratory studies. Immunizations should be updated and smoking ceased. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H515110#H515110\">",
"       \"Overview of the treatment of myelodysplastic syndromes\", section on 'Indications for treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H515117#H515117\">",
"       \"Overview of the treatment of myelodysplastic syndromes\", section on 'Management of asymptomatic MDS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Supportive care is an important adjunct to the management of all patients with symptomatic MDS and can be considered as the sole treatment modality for a subset of patients with lower risk MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link\">",
"       \"Management of the complications of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a high (&gt;4.5 to 6 points) or very high (&gt;6 points) IPSS-R score who are eligible for allogeneic HCT and have an available related or unrelated matched donor, we recommend high intensity chemotherapy followed by allogeneic HCT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If a donor is not available, these patients may be treated with intensive induction therapy alone such as that used for acute myeloid leukemia (AML) or with a DNA hypomethylating agent with plans to treat with intensive induction therapy at the time of AML transformation. (See",
"      <a class=\"local\" href=\"#H48546547\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H48546554\">",
"       'High intensity chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options for patients with an intermediate risk (&gt;3 to 4.5 points) IPSS-R score include those used for patients with low or very low risk IPSS-R scores and the more intensive therapies typically used for patients with high or very high risk IPSS-R scores. A choice among these treatments must take into consideration the patient&rsquo;s values and preferences and their interpretation of what constitutes a reasonable survival and reasonable risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H17341115#H17341115\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Intermediate risk IPSS-R'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with scores high (&gt;4.5 to 6 points) or very high (&gt;6 points) IPSS-R score who are not eligible for allogeneic HCT, we suggest treatment with a DNA hypomethylating agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H48546561\">",
"       'DNA hypomethylating agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with therapy-related MDS are treated in a similar fashion to those with therapy-related acute myeloid leukemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"       \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients are followed longitudinally to assess disease response to therapy and to monitor for disease progression. Standardized response criteria have been developed that use bone marrow and peripheral blood analysis to allow better comparisons between published studies and to help guide treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H515592#H515592\">",
"       \"Overview of the treatment of myelodysplastic syndromes\", section on 'Patient follow-up'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is a general lack of effective treatments for the management of recurrent or refractory MDS and patients should be encouraged to participate in clinical trials. Outside of a clinical trial, the management of patients with recurrent or refractory MDS is largely dependent upon the patient&rsquo;s prior therapy. Patients who have not yet been treated with DNA hypomethylating agents may be offered a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H48548443\">",
"       'Treatment of recurrent or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/1\">",
"      Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/2\">",
"      Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/3\">",
"      Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998; 12 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/4\">",
"      Oosterveld M, Wittebol SH, Lemmens WA, et al. The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups. Br J Haematol 2003; 123:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/5\">",
"      Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/6\">",
"      Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/7\">",
"      Spyridonidis A, Bertz H, Ihorst G, et al. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (&gt; or = 60 years) with active myeloid malignancies. Blood 2005; 105:4147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/8\">",
"      Tricot G, Boogaerts MA. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 1986; 63:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/9\">",
"      Wattel E, Solary E, Hecquet B, et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 1998; 102:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/10\">",
"      Wu L, Li X, Su J, et al. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma 2009; 50:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/11\">",
"      Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90:2969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/12\">",
"      Knipp S, Hildebrand B, K&uuml;ndgen A, et al. Intensive chemotherapy is not recommended for patients aged &gt;60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007; 110:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/13\">",
"      de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/14\">",
"      Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/15\">",
"      Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010; 149:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/16\">",
"      Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (&ge; 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010; 76:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/17\">",
"      Gr&ouml;vdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol 2010; 150:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/18\">",
"      Raj K, Mufti GJ. Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2006; 2:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/19\">",
"      Itzykson R, Th&eacute;pot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/20\">",
"      Itzykson R, Th&eacute;pot S, Quesnel B, et al. Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. Blood 2012; 119:6172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/21\">",
"      L&uuml;bbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/22\">",
"      Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009; 113:6296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/23\">",
"      Kantarjian HM. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience. J Clin Oncol 2002; 20:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/24\">",
"      Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006; 107:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/25\">",
"      Fenaux P, Mufti DJ, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 Phase III study (abstract). Blood 2007; 110:250a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/26\">",
"      Ono A, Westein E, Hsiao S, et al. Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth. Blood 2008; 112:90.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/28\">",
"      Ad&egrave;s L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009; 113:3947.",
"     </a>",
"    </li>",
"    <li>",
"     www.aamds.org/aplastic (Accessed on July 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/53/9049/abstract/30\">",
"      Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011; 29:1190.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16121 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9049=[""].join("\n");
var outline_f8_53_9049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48548729\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48545776\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48545783\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48545797\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48545804\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48546540\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48546547\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48546554\">",
"      High intensity chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48546561\">",
"      DNA hypomethylating agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H518259\">",
"      SPECIAL PATIENT POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17341143\">",
"      Intermediate risk IPSS-R",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48547460\">",
"      Therapy-related MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48547467\">",
"      Patients with 5q deletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8347533\">",
"      Chronic myelomonocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48547509\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48548443\">",
"      TREATMENT OF RECURRENT OR REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48548464\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48548729\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/16121\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16121|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/9/1183\" title=\"figure 1\">",
"      IPSS risk class outcome in MDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16121|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/37/27228\" title=\"table 1\">",
"      IPSS in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/16/20749\" title=\"table 2\">",
"      IPSS-R in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/5/14427\" title=\"table 3\">",
"      Survival MDS by IPSS and age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=related_link\" title=\"calculator 1\">",
"      Calculator: Myelodysplastic syndrome international prognostic scoring system (Original IPSS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=related_link\" title=\"calculator 2\">",
"      Calculator: Revised International Prognostic Scoring System (IPSS-R) in myelodysplastic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=related_link\">",
"      Hematopoietic cell transplantation in myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=related_link\">",
"      Overview of the treatment of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=related_link\">",
"      Prognosis of the myelodysplastic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_53_9050="Early FGS Tip lesion Light";
var content_f8_53_9050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F66716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F66716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tip lesion in early FGS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph shows a tip lesion (arrow), which is considered to be an early change in primary focal glomerulosclerosis. This lesion is characterized by epithelial cell injury and foam cell accumulation; note the enlarged cells with foamy cytoplasm in the lumen of the affected capillary. The lesion occurs at the \"tip\" of the glomerulus near the beginning of the proximal tubule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD9AYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1C+8maG3hV8yzNhyOB+NLDYGK4hS0AVm+8c9ua6DU7Ow1LSWu4mWMKCwcetYmnC9uEVoI2YgbRIRjOfSqjO8dD0ozb20OTkvLiLWrm1mJxuIAzU0zxWYaScgAjDZq7q2lPHqCtcoElxuLbuSK4nxsl6+qp5UhW1jT7o/iz61304xqNJM6MRVjGClE6J5rbU4GuLOXdd22CoHcDt71p6dcxwweYwzDcElWPRWxyK53wLZPPfLtzFCeWJ6E46fpW74g019KDNbyCW3lJJi7fh6VM1Hm9ncuhU9vBQn8iadDdho5jiNlzjPWsS+0do3WSEDJJwPQVr6e0MTxLeFmjdf3TE4yP7prnfFOtyQXslrAQhAGST7/AMqdJS5uVBKtLCleYvDJ5U+RjpzVjTojez/u8lf7xPSqOmvLrenzs+GaGXy1b1GBXU+H7EwWkhXkjBPHb0rWcuReZ3fXIzoqa3NKLMUeFO1uAMnmuV1xS/iCzhZgVL54rqpR5ZwzdBkg9RXNaJbnV/FpkiXdFE3J6+3WsaWl5eRlhXZub6I9i8M2i2unpgZ8z5qo/EvQW8ReEbyxTG/AlQHuVOcV0drCIoI0H8KhRzVbXLlLPSLy5kOFjiJ/SvHjUarKcd7nhS/eSfmfNvgfRnsI72Rk2mUiMn2Bz+HP8q760tVkjBn5K9CRWTb+a7NE21Uxkknpntn1qO91grEIY2Kx9B7gV70+apK59Dh8M401Th0Na6uLW3gkkUebMowinoD0ya5uTWpQqI4AZVxlRjJ9T61Rvr7ZDGzKczE7VB+Zqg+yCC2e51aOdZG/494V5L+pNXGmludUnRwseaqJrN/MmnTSpvZQdvHTJ6Cs/QNKvNa1AW9plyhxMx6IT2zXTR2baloCafc25xLKskSoNpLA+tdx4anh8KWgt30prbJDO453kdyfxpVK3JBqKuzzKuLxFaanQ0j08zJg+FBiRZZ5jx2Fb1v8KdLe0Ilkk88jG8Hoa7PTtf0/UFVIrhVc/wAJ61orJGzhEcEeleRUxmI6uxyVcdinpJtHzR4l+FPijT7uQaUourfqGVsHGe+aseHfh/41lUyybbWPHyhm5PPfmvpUAEkg5Pr6UbQV2nqPSr/tSo42aVzGnjK9N3U389T5w1fQ/F+hWjzzQmdFbHyDccDvXMweMNRhk33FjONvRmiI5H4V9aPGrqoYAgeo61Tm0ixlzvtYSPdBzVwzKO043OiWaVn0X3HzXofi681a+FvDCWuGOQMYNWdb8I6jqkzz3WnT5chmw5+YivdrrStF06+guRaW0Uu7aGwBj6CtopE67lCEEDBxVyzBRacI2uEsa5wSqU0z5w0fSYdBlXbp8sPmDBfburTn8RWi7khuZWQjDBjkE969o8R6DFq2kXNomIpZEIV1HKnHX9a8Om+Ht3bXZghgkkC8E45IzW9DEU66bm7MFj4Q+Gn9wlrrWlT7Ujk+dDncBVHxRof9vvHPZ3wMW0R+UBg8d67zwB8MorH7ZcalH/rkCLE3OBUniH4b/ZLSS70W4MUsYLeWTwe9V9apRqcsZG0cRRxUVGto/wADi9A02LRbPynfLjBY+vbFdfp9wsqmIM4Y89f8+v61xpv5UVoNShdJM/ex3Fa2n3a5RkbJ/vg1dSLlqzuqYa0LRWx0wnuPMYI4RRxhTwKsWchkiG7crSjuO1cze37BHOAshbnB+U1oaQ0/2UzzccfL6dun8655U7RueZJOMuVo6q2VIlYgZYcAg+nNc94w1e5so5PsEixytydw681V8YeMH8O2lvDYReZdTL5hdhkYrnbbW77VHtm1yCOWK4k2MqrtK5HB/WlSoS+OS0OKpVTfKty54C1nUh4ktk1GZJbS6PlkE9Seh5ruPGmmLbOk1uSM/Mw7daztO8O6Zp9y0/mkzRMJIhnOCBwKL3xEtzeQ2c0RkRzvZj2A6VM5c9VSprQKfNB+8U7q5by1nOQUGAMc1jxx6jdyM3mlcjjd0Wuh1mCEIHDBiMnH+faqtru+zb0/ixtGOQK0g1bQ9Wjy8nNYW20S18kvezPcP2DHgfhVHW5ILaJAoCpjjHp3qS+u0tI0SWYo+eQvPFc5dLdatOqLG0dsTgFvvNVwi27t6HRRhrzyegyBbjVrgiJmSBeDg9a17LSLRlkadXZl4VvepLO2ESRW8ZCryOnJIqa+uFsrK5k2cKN4XtnFVKTbtEivinq46IqSae0eNruuPX/PrUtrqsmmT/Zr0iSNuME5OK4y317UZb21kDq6u2XHUcdhXS6xp73kqSA4z+anFVKFrKZy08b7XRq6L88SWd6r2xzZTkEHspNbrS6HaHy76eUzdTg1zmiESxz6dcnJB+QmsjUY7gXTrMu9hxuJ6gVk6fO7NmuJozn8Gr/Ndz0y+vx/ZsFjZKWtlG6ZiMZwfuiuptdWsFt4VjYRhhhQRjpWPpC20pX7YM7Y/MUL0Ap+nWtlqFyzIhECOVQH9a82fK1Z9Dz6kY7M5/xP59zdFmk3DG0EDPGeBWZLcwXwEVxGpMaY5HUiu71XR1W3m2sqRbc/N656V5lqltOt1JJEm2IHAK9xXZh5Kasuh1YZQqx5DSEsdrC77dkajp0qCbxHb6pbR20iuityjHgg8c4qmsq39g1vJIIpOeScbqrWOkJbXC+Y2/BDKmf0rdQild7iqRqU6iUVsdJYyQ3EMelanEFmBIjlXo3cfjXnnjDQ7q01mS7ljknjC+XnPB9Ca72/tWubcYwkw+dCD0Yc1NeX1te+FtS1C4C/6Pbu8in+FkUk0qdX2T5unU1qRjVh7+35eZieCdOhtNFkiuWCTzM0gAOdp7D8q6KydrdWXGd3Bz0xXyrpvi+TXNN07Q9TvjZp5mby9klI8yJeVUHsx6E+wPc17vbatearpqHTZYrmzb5RPG4dWxxjIqf4zbTFhqMKqtTemm/+Rp+IdVCL9ntjuuHOAF/Ku7+Gvhk6XYi4uf8Aj5k+Y57Vyngnw6i6hFdXzb3Vg2evP1r1bUdV0/RbYz6hcxW8K8Zc4rnxdSyVKn1FjaqpR9jT+bL4IXcM8Hoa8++Jms+ZCunwsCm8NMR6D+H86pa78QheOsfh9SYf4p2GN30FcVJcyzXHmXYPl5LEt/E3NLC4SUXzzFgsDJtVJ/Ih1G8aCFVj5yfmya5zUbzMYyxV8EcVPq1ws6Lh8EE7hn34rO0qwuNc1eGxtdpkk42166Sirs+khy04c0tEjW8C2z6p4gg81DMhRggPbtmverbwdpx+ySXKebLGmPm6VS8MeArHRJorxmZ7tV+ig49K7AShY8kHgV4+LxXtJfunofJYvEyxEm29P6sed3dqo8exwRAIilQu0dOM1vasvmTSQXSqyg5xjr71538WPFtv4O1u31WRTNcMQLe0T7879gPbkZP/ANYHmfAXiO/utVvvEHii9ml1fUyE+zo5W2s4RyqIueo7t/8AXLXyTnyuPY0lJc0Irt9x2es6c2nkXNo5C5JBHQH/AArkItd1y1v47y3vJJQ0oWSPPA/DtXq1+LebSJGWVDE0ef8ADFeQ3mtroltfQJbxyTzMDE/cfX8q68PL2kWmrs2qxlXp3vbl/I9Un8aSWcKh4t8rYCrnnJ56UQ+K9XKqxs2GRyNnWvIvAXidZPFsA1VknAySwzhOK+j9IW1e0Royknqw5zXLiacMPo43MnOjGCko81+pyUXxAEUoXULVoge4BH8617/xdaQWccyDMbgFSSOa1tZ0fT7+zljvIIyhBO4jkV4DpMzm7lhld5LSCUqr5yAM8Gs6FGjXTaVrGmHoUcVdpWsdTf6teavK08+4xhjsXpxWl4e1+4srm3gu5Ga3ZwOe1WbDTYbpVZG8yNhxt61j+L1gsDbR2uWn3ghAck4710+5P93Y6/3c/wB0keuLcRCBpjKqp3YnAArz/UviEy3k6abYmS2jcp9ok6MfYVmaPZ3niHS0u7y+kWGQEiJOMYJ4NS63ZwxaSkFtDiMHGc9f8e9c1PDU4y5Zas46WFpRnyzd2bdh4z+2AQrHiVjgN2H1rpLC1LhmuZfMDDOCcjmvH4ruLTo95BMzHCAfqa7bwnrFzcQMTG+yNtpJ+hqq+GUI3hoZ4mnCEnCkbeu+G7G/UExKpPAyOTXD6h8OjJAZ9JnMcw48snj/AD/9en+LfiGIpfItgY3ViAGHXFdX4d1/TbyCDfdwx3BUZhLjrilH6xQgpEUsTVoq0X8jyK7hv9NmMWpQNvX+NOnpVzTdXnjXy0KTW+MkE816z4g06HVFXao2MCGfHbtXhvi61n0/U5XskljcHIRVJzz2xXbQqxxCs1qd8cfSqR/fRsdVdLp+vwRJLIYLiFSqE9vY0aZpkseoW0urTrLHAQUEa4DdgDXH2WrTowh1C0kidxgO0ZA+vtVjXrvUrC0im0uV5YXJLKo3FfTitPZSXupnPXwdGzrReh6dqEtvPdbrcHYoyeO5zWFNoUYvxOk5IU4AHp6VyHw/8Ra9qmuGwlsy6PH80zRldldlcPdxNm4JtzG2Gbbj8q53TlSly3MIUo1tYvQdrEqmVUj/ANa20BV9MVBe3v8AZNiqDDO3RF78/wBKqi+s7V3Z1d3X5vTP41Aqte3Rup9pweEU5Ce1Uo6Wex6UaappKey/ESw06W8la5vsbwCwU9BzU1xdGH5oSFwcrx3FTPIVR1J/dg5UZzism7+afcVwGGBjuapLmeo4N1Z3lsSx3uCpbqCST7+tSLNDeW8ltcDCyDBwcGqUds7TCIjk9D14qS6tzbHOf4tvvmraRpOjTl7rIrHwza2NzHJ9oaUK25I26Z/yK3VU5G1hu6DPesOKZxMjMxO08ZPSta2mLhS5wVJPFTPmerZyPCqivdK+sW5iEc8J2zoeTimySvKEeZPMYqPmwOf1qXXJytkoBdguPlPXJ6n+VCpmKLd12CiPw3Z1Un7iua8msQ6dqaQhz5ZwsjDp/wDqrs4NQ02y0hZoZYZJs9Izkk5rzDUE0uK9e03u1wWwMDIq74buRo2p7Lu3DrKoHzAZXNc1SgpK6/4c5q2GjOKavf8AM7W6vptYMSTRNb20mCrE/eqpfW/kzpFEEl3HKAfwjPJPtWjrLpLbWrooEKEYKjhQOgp2jo0UcsoRWcggD+6v/wCuueMuWN0cMW0ro5PVvC15LepJEYokdsbR0WsTWNGu9LjNwzCSMHaXU8d69C1nVFWJVCBQuMjPOcda5DWNaZrNrRSSpJbkDqa66NSpK1z08LVrTaTWhBo98JEEb8MPWuJ+Kl42j+GNdkgLLFd2hiYDuXYJ/Jj+FdVo28yPK2OwPHT6Vb1iQQ3OnzrkSLMFAI7HrWjWriupU4rnlTXVHiHgH4Tm2SLWfG0RS08sSxWAJDk9vN/ujGDtHPPOMEH1238UWqwfY4rJbaGFQqmMAIFHAAHt7Vva3NA9qLORS7OSXycYGeAPyrBXwylzdwzedmMoUMQHAzRRhTjH3jgVGdC0qa0/Myrrxlq9vP8AZ9OAjRidrFMn6j8aLHS7rxKiXPiJp8l/uMeCB04rpNQGlaXfxWgMKXDp8oxyB61oxzpLbuIxwuD0xzWjmkk4K3mbxptvmm7+Rmiwt7FQIz+7QYCDoMVha/J5kkgRgkYHT0Pc10N7dJBC7uyrJ/CP89q5LTNPv/FOom2sYwecM7dFHenDT3pHq4eKgnUnsjC02wutSuxb2kZclvvdB+Jr2z4b+AX8O/8AEyuJVk1B+Bt+6gNZ1n4TlttmmabNDb26MPtV65+dzjlVH1r0q3u7PS9PSITiQRr1LbmNceLxLkuSHU8jMce8S+Sn8K/EmvdStLC0jl1CZIInlSEMxwDI7BFX6lmArmviL4603wJo32q7DXV7cHyrGxh5lupT0VR1xkjJxxkdSQD4L+1p4+juv7I8OaQ7xGKT7fcsp2kN0jHH1Zv++ah+DPjPT/FHi641nxQ17qHjJx5VqTalrazh6YiC52E85ZgOvXlifPVF7M8hay5Tu/DXw41bW5p/FXjV47jxHcpiG2BzFYREZESDpuwTk+565Jbkb/w1NaXMtuD+4LZAY4KV7zpN0nlNG0hL+nWuF+IenSySvNaQlvM6+v8A9avTwdWUJOHQ9KhQhUfsqnyZnwXSWfhyK3SYySJHh887Rj1rlD4avNbha8bMSsSY3Y4zVqz0bUDKkM7BIXx5iqc4HvXeeMdcs7bw9aW9ohSVVCeWOQpHBrp5nTklDW56UoRhH2NON7nkMfhu80oW0cogjIkEgZeZHyMYJr1rwr4X1b7IsiXEsTMAwIkOBmq/gDw5HrN2b/UsuiqNmTzng8V7FahY4FQAKQMVy43GNe6tzhrzhg06NL5nmmu+HfFS2Y261JLFj505Bx9a5aNBo0DWEsKrHKwDNjJ4/wD117pLJkZI4HevLfiCba5LvAAQxxuXpkcZFZ4Wu5+5JF4Gu6suSS+4zbS+a1iYWpcDAPB7Vq2kll4f8P3Gv6sPNu5N0cKNzn/PNc74LhfULyOGbdt6MO+Aefp0rR+K2nDU9X07RdKYrII8yoRlUXoM/lXRNJ1FTfz9EXjJP+HT3ZU+GWotqJ1AurQaezl40XjBPYfWuh8VCe0s088qp+8q/wAWO2fetPwzYWWk2NlYiNP3AyzqMbm9T+Ncz8QtXtB4hiW4f90qZKqc5YDoKyUvaV7xWhnTm/aXlsl+RzWraJqhnjcRTG3lRWjlQZKHvXoGhwy6T4OvJ7hw02zLfU1f8Ga/bahpDWrRSGa2ABQryQehqr4tQt4cvlZCiyLtVSeh9f50p1ZVGqclazOOHv1HLuzzjW/B+t3tm+riDfbiNmVFPzY7H8K86gZkt7ea3klS7gYBl3fMWya+iJ/iRp1lpsUb27O6RLuA6AdK4DwxpularqM+tyQnyjctIkAHykZ4rtoYiai/axsuhNSjKq5WVnE9t06QHQbVgPmaFGwevIGf51zGu6vZadfyG4tfMdUC7eOPc03xJ4idJEtLABHRAWOPu5xgflWDo+lXmuawz3LkoOWYjP8AnrXmUqKinOeiN6GGSXtKuiLd3rvhvVrdIbyMWzMSuW9fwrldQ0LUdLgur22hmaBeUHqPp+Ncl8RdMudE12+tM5DodrHsCNwI9692+Gmpf2/8PdKluR5k3kiOUOO44/liuqq/q1NVIaxZk8RKjNqlseUaN4xCTm1l3Ws5xkjjg+tdVKF/s7ElwZd+dvfHpV74j+AotQ0yW602PbcINwVeDx71xHgTVWVJ7PUIneS0PCOcbiKtOFWHtKfzR0Yesqzs17y/EZLbPcxSnPzBsZ+napNFjms7lI3jfyyhBzxnjrV7wtH9vhMtxhUaZ3bJHr0rf1AxNF5joPIjGwKeDxzmqnUs+VmuJV6130MC5m5KoucAAk/pToIJTCssowByvHWpPDtpJf3TvEm6IHcR7V0msoi2XkLCd5AK8cAVMpqL5UdPNGk1BHISSHzQyKxx0PpUM0rXBQO2D0yegrdtlRAXeJht4YH6Hp+lYswi+1SJG+5SSQcVcZJs2hPndmi/DpsVxEI1kCyKMlj0Off0qjBMiTrCsis2edrA1la1dSx2kcSyOivKBIRk8Dvn0qj4Ts7sagn2xMsGbcVPAQ4wa0UPdbbOGriXTq+ykro6rVGGyJFYMxOAAtW4Y444wlyh3rx8uOlU4YlvLl3YEQq21RnkmqGqeIbC2vpYJL6MyRna2X5yOKys2uVG8moRUW7CaSy3OqJNIql5JMjPYdK7HVbTdHLLgbl+ZWHr6Cud8QfZba5ECo8dzE2Y3AxwB/jWpY3pn04SS7j8uCep69ambbtNCxV5xVSGi2KWlajdhpUuJneFmDHcTjI6Aelb9xrv2eCJwxVs4Ow8n1+lY+sRKlhD5BGB94AY5rLs4JLqQKSfLB5J6UckZ+8Rh8ND2V5HaSyJf30cT/KXyxLfyzXI66h/ti6VU2YfAXNdFC0kEiTtuMedqt/e9RVS4sUu9a3M5jjc8tjJGBnP9Kim+R67WFhqipyb6EGn3VnpsYtp5M3J7Hp9c1Ut0Gpa3vkm/wBFgYMO+TxWB4iiuodRdTG7xkEIQnbOAc+1V5ri9sNAWaFHk3TsGCKc49K6VS6p6s56WJb9pOXQ7/W44jcecBtwAAwPA+lN0o72dS5CxpuUZ+92xUPgWO4fw7qk2tfNEIysIYfdb09ar6Q8gtpBncBhdoxmsbbx7HThqntqOnQ5uLTtXuviOt+9ttslUhnk6MmMcV2f2mPTYrgzRDeY8IPr0pst/DZWYeViZSmPpXD6trNxql4UhIWMfePbHTmtLOq7taI2wmEet9nqMvJ21PUYLdCSWcbiDwR3rvNOv/7Nga20eJI0UcyH+I9+a5rw94WvrkefDDNsbjzSuCw9s9q6uWx+wQBJQ6kLnDDpmio4t8p0YidOo1BO9uhDZwXepTENOMN8wI4xzSXWnX+mMZpmkSMk4ZwdpxVDRdSksvEVsEXzI/NVe3zZPSvYNe8i50K9Fwu1BEzYIxjANc9Wq6U1G2jOHEVXRmo20Z8tax8MV1XxJNruszvqf26Qu0EeY1hX+AZBy3AAyMfSvoX4eQabp+gx6dp1ha2McYy6Qxqm4+px1PvXA6Qs2q2tnaCSWC12fvJVHOAec1oXNtbWjO+hXd0ZoTjaW3F/WlVoxkuTZ/1uczwMVNq+/wDWp6LDDbQzu0cSgE84/pWL40v4baAlthBBHvk1P4IvP7bsZPMYq0LDIA5/OvJ/ilqd3a+NxpbSk2oQSRl+ARj2rGhRc63I3qjOCjTqtVXaxrah4lsLTToEUh7gj5sKAB7fjXGapfz3dyry48oKMBe3P869G8N6LoOv6RBcxxATL8rcg5P0rI8d+GZLV7RI4wkcpKqxGMHriu6lUgp8nU9bDV6F+WO77nffDy7iutL/AHQjV0IVhnnoOa0fFmsx6baqonAlJ6K3Irw63tfEGlypHatKPPPybCQTk9K66LwWyWc15rGpbrqONpZI95LA4+7/AErnnhoKpzyloznr4SlGrzyno+hYv/H8l5/osLeUnCknq341TRptUmS0s4hJJIcgdce9cJZR/aGRovmwWbaT2FejeEdP1lbea9stsSopHK5Le2fyronThRj7uh11KVPDQvCy9S/aRjwjaSkRiXVCBGnOQSx7/jXVeHvDcK6eby8mNzqN4BLNcE85I4A9APSuKtorq+1R1uizTbxgMMc9a6S3vrq2t2gSVkAHIBGVNcdeMmvdevU82vSk17stWJfXdpp09xbSTF5YsFccDn1rxbWJrm71qea62sAzKjNwoJ/+sa9STw/earNLLbqzIcYkb/PNIngiQ3MRk8sRBiW3jOG244/IVvRqU6N7vUyxNo0vZwd27XJvhfYT29zKZCJYgn3hwOcfnVz4g65b6fZS2w8tvM4IJ+6TXSXElr4c0ldvB2hF/wBtsV83+Lb/AFLXtd1FnyHhm+4CB9MDv0rPD0/rVV1HojlpNUl7Sa0WxDq4FyzQTStEApxh8YGc8+1dJ8O9Xt9MuEgdxLb+YGUZ4rznxBBJc3MN2inyjGFbHO1sYwa6PwNB5OtWfmKWDspMYPTC8V6lWC9m0z1KFVYipK0LJrVnrnil0tr+e8tSHWUK7AYwhxTfBXj2wRHgvswuT8rlePxxXKeOXbw9Mwa9/d3KEbRyVB5x/OuF0i7S+b93FLEu/Ypk78Z6dq44YaNWlaQqbo1Kap1XZvbueweP7Kw1ryrosksrL1HO0ds1l/CbXJdI1e80q8UraykPH/s9q6D4e6FDcaZ9ovCZVY7V6gemK5T4m3SS6nJ4Z8BRmXXoVM2oXq8xadDjnce8h7L+Nc8qsFF4eWpz1XSg/ZPU9vt7q2u2lFtcQzGF/LlWNw2xsA7Wx0OCDg+teZfE3w/Bp0kGsWcCp++AnKjqp/ya2/hXpWl+GPAMH2JSqNuuby7mb5ppD96V2P069ABWib/SvHXg2a50S6F3Yz71jlCMAzISpwCAeoP1rhozdGp5bM5KE3QrJvoeO/2wuhW9zEArt9pCwq/A+YZz9KX+3724ma31OGNBK5gWSJsgP6Gsl7NtTaOEgG6Rti7hwWTsfqKt6boGoswlvBGkEMxmEa5JJ+vTivdcKe73O3GKrDErl2dj1LwKILfwvdsdv2hW57nGOBU1yS1izIA8uMY64NUPBU8C+cNzMxAyuB7V0ZaziV/tDbd5BAxyR6ivJqXjUbJr3jVl5nFjbBLKoZWZhlVPb2rm5wqTHy2y2eR15rrNWtbeRZmto3CAHGew7ZNcr9knQ7greo9a7aLurnoUNuZsgKeYcsFZQc4PNbEDwxRyMqKuU+YoOtRWdshyRuLgE5NQatLM/kWFmubq6baoxzz3q5PmdhVUqs0gi1C2tNGluJHXdHnYmep968jlk1GKeUW0SzIzlt525yea+m9H8A6ZBpYj1GJZ5mj2sSOBnuK8o1jw1Y6Vq97ZH5hFKQp9sDFVhcTTlKSiefiIrGz5afQt6uZLllk53rx83Gfet7QowLABlDMBnr0rltTM92AkG523YZF64rQ8AWV1dzSNdI8EfKADgk9uDSqJKne+x2YysouNGxtyRyXk80MOAu0kA+1WbG3WIRgjchUBh+gP4VftraKCeRMqX2kFlOaIoma0ZQyou7bnrt9DXM5dDnc2o8qOck8Taepe3jaSWCN2jZwOA4OOO/FbsMoIR1l5C8Nt6/jXmE9v9gS5sVtZ/tjnAZl+V/8AaHFekabFLBpFvE2CEUDdzwe4+tb1qcYW5TjoVZTbUgv1/ds7goxGFbHFc/4RuxDDM0i+YkFwWBHO/Jpdf1IqTawFjJIPug5xWjpNkmn6SkUqASNmRm7ihRtDXqezSp8tJ83Usaje3V6ZTuKQKcqmcY/xqrpb+QjHO04zkjtSzSo4VA2Yiu5j1rn/ABPr2WawskLTBedvr6VUI391G0YLl5UtCp4gkm1KeR0ci2jbYAo5c+wqPTLOC3vtLkvEcW0siMRu4YZ5Bqloeg6lq+r21taPJFPJHuDPkLGa7+f4S6zcC1jmvoAIGLiRBznjt+Fa1J06S5JSseTUzSc5qMVaB7UkcTQR+SqiPA2hQABXn3xSxZxRPGw+dSpHHH+eabNo3ie0VfJuZ2IAGVlzmuO8UNfibyNVMzkAAbh615mFw6jU5lJM0wmGUanMppnLWet+Rq9vIqM3lPuxjJJr0XxB4/t9T8PyWlrmK4lGxz6V51BoEPnfaILhwUY444Un0ov9OezjiZmcrJnJI4J9jXp1KVOck+qPQjCNaS9uveT0sem+AkgkspbaS5iVJU2IcYPHPBrfh0C106cXdvMjxjq5ORmvGdMh1DULlrO1lbEY5Cn+WK2tPurnTbb7NqVw6QAkhd3H4+9c1WhJybUvkZ18LJyclK1+h23hKT+zPGF3bw/Pb3BBBX061R+MvhqHW2ttTWOeNrTKSTIBkr3H/wBetD4bWdtNJLqUlwGk+7Gu4HA9au+LtfXyr3T4SjloTtJGQzHNc/M44i8N1ucFZKddJK+1yl8HrDT4NKc21x50wcj58EqM8f8A660/iwsTeH1LMBPGd6D6V5Z4Au5NG3XjSsqDDPk4GQ1WvFHjBtVlfcRNEmFG0/pWrw03iPabo6FgXTxKUHojT1DUPLk0xEgbdCu4nPX0wfzq94jltrnTL640+d1vWhCqmeP9r8TzV290v+3/AA5ZaxpKLGFi2+Wf4iOPwrkLXVzb3CM6ApuYPH02kHkVpBKesd0bQ5ai93eJz+jQ2lxcWSKHADATb+MHPP4V9JaV9hgsIYrRo/KAHC968EnsFuNeu5LSR7bSpyGkfbuCZH3c/wCeldppGma/4dvI7qNBf2wQ87iQwPORUYyCqpa28iMxj7bl1t5F/wAWs2l6hHqJTZG7YPHf/wDVVu5e3uo0v1b9zKqkqnG49/pWF458Uw67pcdkttNaBJN1xLMhCxgdvcmsODxTZ2kIikSQWpCqJUyfmBOcj8qiFGcoJtar8jl5lGMVUdn+h6ZH4gt7e1jVLfYqgAoCOPpSWviiykmaFuJnb5FPfgd64WxvRe2zXL4KLng9/en6DDHqmvwCHYqICxJ7Y6VEsLBJtmksHTSbl0O18YaW2paPwWMsZDjB4FcDpfgrSvFVq7sjjVbdwDMr7fLI6H36V6lEVZ9rElh1wcKBXKaPex+HfHF9ZXS+VbartkhkYYHmDIK+2R+tZUas4wahutTjjJypOna/VGM3wvubbR5rS1uIDGW80hwSxfuS1ecahp954f1RfPjMN1Ed49x2I9q9o8dePrDw7Z3QgP2m5ReRGeEz6/4V5LrnixvF2nw6jc2iQF/ki2nkgdc/ma7cJOvNc1RaM6ssxE+f2PRm54k8NSeNvDsGqWjIb2NNrRtwGGOo965q28Kr4X1PSYPE94kFxq1ylpawqejFSQxPpkKv1cVo6F4iudKjW36xKu5QeMHvxXh3xs8X3fiXxtGsUz7NMUQQCNvuyZyxGO+cD/gIoq1KtGPKnp0IxtJ4eXtV30PebrxFq1nqt18P/CEsB1R2PnX7ENHp0R5Le746L61r6zBp/wAMfh3f2elbmlmRvOuZ8GW5lb70rk9Sf0rwn4deI77Q9Rs9H1LTk066uke4+1zuySSE5O+QNk87TycdvxveI9fvfiHqMNtPPLF4dgJBmQEG6YdQv+zn/PphCkpyU932MZOHL7eTvLt5/wBbs9F8ItrHxe0bTtHXzdN8Dacix380ZKyanKvPlJ3EY7n198Y+gNOsbXTbCCy06CO2s4EEcUUahVRR0AFea/AFZ7Tw1cWH2do7SKYm3BwMIR1x9a9RA3kHcRjPHauHFQcaskziae8t2fO+pFdP8UazDHz5N15iFvQn/wCvXYPL59rhJPkdBuUY/IVgfFGGLT/HBkiH7m4iAfHc1h+INX3Q2luJHWEIAyRHG445yfyr2Ix9rGLR7mLqqNCFY7bw6htr6RWdYleM7c9c/wCRW9qBSaPdGemOSeQMeteV+Dbx21Au0kktqu0necgHk4B+n8q37/U3S0mvLiYwW+/b8oJLE9h71NSg+cmMlWgq8nZFy8vXjcQxneOh5p9na3d47bAAg5z35rI8Oz21+8joxdoz86t1X0/GtnxHrlxoNoi2oWGXJ3Puyx7fjRJNPkitQrYqMY3p6osC2S0jkaRPmjGG5IxVP4fsl/42+2zj5VBWDJ7+tcvJ4pmvzeWtwJDI0Sur4Azz/wDX/Sq1zrFzpt9ZWOnJ/pSwm5aQdExk5J/A1XsZcri92RCtB4eVST30PovUb6HTrZ7m5lWOFB1NfPviPVpLrWbq43BfOcvtx0BPH6YpsPiu91m4mi1SZrt4NqxGGTdGxPoOma6Ww8NzNbLI6h5JPmfK5wfT+VY0aKwus92GEdPDU/bPW5hadMIdXZ0YFS+dyn1zXWzbt+9HPHzHB7fhXB6ajraWkzN95QenXmu+gQS2p2k/OB8/4c1rW3udGKXNGE+6EsmWSVniUjK7Qzdc1Q8TXlzpemo8QQTO2Fdug6nPv0/WtWzjjWN4mU5IOGOcKfUVzmra3p2u29zoUdvc3EloGaSWLChB7Z6kYqKavO7Wh5+JnyppMo+H/Elzca2tpeSRzEgMsuwLg9unauj8Q3ZtbAuhAkJxnPU1y/hrw2YZLW9N35toiAxkIQT9a2PFlwjokK8tkHGK1mououXYvL4ym0pj/DeivNqUN3co22Q5XI6j1/StmaKSWG/kY7Ao2de3IrR8E2dxqFtal5NoRSq/7I/x/wAa4Xxh4te38U3OlaUEFtA/lzM4J8wjggY6H3rOLlUqOK6HVXxcY1OWfp+JBq1ybHQ5DGuHZditnHeu7+EHgW3t9MTWNWiE13c/NGr87F9fqa891pG1HV9L0qMcBgWUe9fRukxRQ6fBFCCqIgG3HIrHHVZQgoxerLzKq6VGNOP2t/Q5PxsBpMmnHSBFBfyzfKQoweMcj06VBc+L9b0KLzfEWiBrZCN1zaNlRn1B5FHiB01Dx5Z25wVt2QHPr1NdR4okthot1HcDKzRlAMZzkcVzXSUIzV7/AHnmcqjGEXG7ZXPjDQhaRXEmowpHIgYFm5waxdY17w7qts8Utys28YBUEla5f4a+GLLWZry51ONblbKbyI4m+6cAHJH49K7e58K6LcxvHBb/AGc9MxcDPsKbhRoztd3Ro4UKFTlbd12ODTTtCs1kNs2o3MrtlIYkyGOOuB+FVNQuG1bw++lG2Mc8IJRXX5hzkivVPDeh2mkLI0Y3TOeXJ5I9K4r4k+XpOuW16koid/mboMgcY/KuilXVSpyrXsdNHEKrW5Y3fZs8p068l027E9vMLadcjLHr7VY1KW88T30cl1CZkACho2xtOTk7R1zXJeKbmddYuLmzeN4VlCmFgPmVu4+ler/CLwxNq2hie/nlis2k3bY/lMhH+16V6VaUaMfaMnFV44hzpSVuXr+h2PgCxOhWTLcQstxIABEPT1PYVN4titzFJcLB5bhPvHrkjFN1nwWltY3F3pF7d290q7l3Skocc4Oa8ybxdqk22K7uVaPG0R7MnNebTh7abqQfqLCYVVfepPbuZoykEtvMdqnOcnt+H1qnpXhyOCO5u5dSj+xhCyouT847fyq/qOmXt4iTSxsnQbMdRVG3WaCymtJeEM3mYxjjFeom+XRndWh7XERSW3VHceCvFM2iRWOneVJNasoeVGH3SxHI/CtPxboqyiXWNIjF1ZXLb3WMfMjY9BXEyaZaawsItpsSqBgeYQT6f/qrf03VNW8B3sZvZDc2hGHt0bdgccn3rknT5Zc1P4u3c5JqpRrylpr+J1fw71HT7rRJrGYRpNkhopF6gisvxC+paLeJp/hzV91tjK2svzeXnsD6exrpINN8K+NLcajbgQ3LD5nhkMbqfcD/ADxWJq/w28oQ3Wm6ldy3O4BvNkHIzxz+lcsJ0/aPmdvJrqTCrSdVuel+jWlzL1B/E+seGprC+0V51J8wTxYwfqK8l1C6lhUac6tHOHw4cYC5OOn1PSvpCCx12y01beNpPlwowwOBXAa1oE9tftdXEK/aS+4eYoOT1yDXVhq8U2tLeRnLD08S3ytJ+RPpPhG4t0trG0u2uoHUNKF42nA4598/lXVRJpui3Bju/wB3KB8yr1xVjTdVX+z4IXPkXRcZkGMZPFcf408NXc99BcPdvPtYlWjlABznkj1Ga51J1ZctR2RlVrVUuToek6dd2s8IeyY4DYIP9f8APas3x5pEfiDTY7aGJTdId4cEZRf/ANeK85a9vtK0i5iiZHnRcrnOQf61zOleMtT0zUJpVv3uZxGPMkkJ2H2A9qcMFPm54PYx51TkpbMpah4Q1q2vJZG89WQtuk64z3HPpVixs109rddji3iO35jyeMk17r4V1ay13TleRc/ulZ9wGCx61meKfCWn61o9y9qzW84LNGwHGcHjFaLHNy5Kisd9CvCjN3haT6nz9rWobWYlt8jqDvU/dJJNT6DFomiIFt7GGK6DEyXsgMkhJ65duh61CmkLFpw/tIJAsVyQ8jScyEdFC/Xk5qh5I1KWGFZRO0kxSWHBw6E46fjXoypxkvQwoVqlN3qq7vpf8TznUodb+InjG9uNHsLq+kmkxGsaEhEHC7j0XgDrjmvoL4QaXq+lWt7aeLYtNmFrEkNvDHCC8TdvmGFxjPQHJ716H4UttH8J+GolKxJebSWjiAVV4OAAOMVj+H7yKa4vrq4Kw/apAI2YZBUf/Xrx4RfvPUcKHK5zk3r8r6npXha3gTSkaFQGb75HHP8Ak1rtGvIIb8zWL4S05rC0meSfzHnbfx0A7f59q2vMjLFd4LjtmvNqv33ZnBUfNJs83+K3hNLvQ5r60B863w49cDr+Fea6NZWGs28K3wO8A4ZTg47rX0jcQxzQSRyrujdSpGM5Br5qj09rHxTq2mElTazMYiOMc5H6V6eArSnFwb1R62CaxNGVCp01R09xpUNvZRw6bsjSNclB3J96j1Pw5d6t4cjto3WKaJ/OiZ2wNxBGD+tXNMmNygDcOuBlR345qhqnjq206f7LFbi4jtiVmmDY59Pw55rde0btHVoyxM+Sn7GeiMHwvpOpaRq5/tNFRdhSTYBtY9ePxrsdbjs9RiCzLI0XGN2OPXFO+1Q6lZQXlvKH8xdw3A5xnvWRrl4IbYRQKDcSnaq55GablKpNPZiw+GjNKCON8UahpeihTal5HHCo2Msc5wOOma7Q+AGv7SDU7yd1sms1mmKjDOcfcB9KxPiz4GbTvAGn6rGDJcqV84Y5G48f0FXrbUb690qC1juZWt0gAEbNtU4Xv61o5upBSpS62ZdOCxE5UIWUI/1cq+DLCH+0yLeNY4YlzGo4wScD8a9Os9MvRDgTrHz9wg8d64b4fKv9ozhhhkCtyOce1eufvJQr2jxSREdXO05+lceNqNSsh5g+Spyx0SPHdUsBp8VraggmGNQfQHFbOi3Qa0ZSCzJleSao+IpUe9dkOVP3Peq+mXbwurHLFuCBXQ480D0Z03OgkdRNEFgZS21imBg565rzubTtQsZJgtrNJLKDEpSMlHXHBLg/jzXaXt9Ha6dPeM2FUbj3/SsDRvEU17dr5pzG5wvTv3HOadHmjFtao8HERjKSjJ6m74ftU0/RbeCabDRLyoHBPU4rMijfVdTAdcljjjsKdq98EBQyBIyw4J7+lXfCVhNfX6iBXJIOSvRRxyfSl8MXNnrYeKo03O/Q7vwvKumQmMLhduB9e1fPGjWEl14wvCxZl+0v0HH3iSTX0/Y6XCIxCz/vABzivPdX8NWnh06hcw7jMzFizHjB54rHC14pzS3djzFCNevF/ec/oEfl/EKB5VVzENxwc4GK9Y1nxAljZjyConIwmfXHcV494Iu0t9Su727DMV4UZrX8S6hPqf2Sa3MoRJcKmACPxH4Vdaj7Sor7I9PE041MRGEuiOu8DRvfavPqN6v3TkSdAWPWrvjuTyriHe58kDH0rj/+EumsoUtRHGu4DkcdO9cd4k17Vb27853YxcKFJJ4FTHDzlV53oh08HUnW53ouh0tp4iXwtqc08Ez/AGW6IdkXkPgenr7+9OuPjH8zR2+l7Yw33nk+Ygf/AKq86uPtl8ymZCwAyqjjH5d6teG9Dvbi6Mz2TS2R+WRm4BPXAxXTLD03701qdlbDYeKU6yuzqb34p6pdEtasIOcCNEycepPrVfRtO1rxZqH2m+MkozuZ3XICg9Bmr9hbaHY332meyXAO0RglgfwHeui1vxqxsVXw/GLKGOMm4lmj6dcBf8ah+5pSjv1OaVRUlalBLzPPNb03S21pba5liijLYw4GQfQV6F4N8Rf2DZjTW2tbRsSgJ2ECvNfDNidY8bWavOJZrqXzGmVslI8enbjOa7Dx5G2q+P5bPRpkggFuZJpNwAbYADgnjPP6VdaMZtUpdrnn1MbCpzc0Pd/E2vF3j9JLeS0tkKeZgbickj2xxV34beFLC4MmpXluskg/1YbkA+uPWvIJ70yg2+nxG5+zSsiTH+IHoTx2NepfBzX7ua5+w3o3TMCG+XGMDqe3asq9F0qL9np3HVxNONL2dDRtXPSNa0O01G1ZGiXzVU7CB0rxi0tLaXSNRtdhfVrq9+yxEj5VAYZPp616J4z8b/2Jcz2kEG+aNcksxHUduOteZ6JrSi2ivipDpf8Amujf7R5/z7VhhKdVQbe3QMvnOSlFPazIPE3gjWPDaJexy+fEhBLx8FfqPSqCQ6nrunI2n3Ekl6hPmQ45VeTvz+le0eJ9Y0+TwzdySTRM8sOUiVgSSRwBivDLC+utDv0ltGKTBSDtwcg9RXVh6s6kbyWqOzklmFBxqq0lszpvD9pNomiQX67RcqzLPbg8uuTz7HFbNnqt/ryPbafcTxuWV4kz90jB5/KuKu9UmutTZluNsbxdHBwzE5xj1Hr7123wf1O1e8jjZ0Eu0rtb/GivHlg6jV2Zq0KbTV5R7lrxR8Qta8IG1g1W0tJfNBAkJIHH9ea568+JP9uiIXix26SDaoByuT/WvYPEvhuw8S2nk3io6kYyQG47V5NrPwPSGeM6TcnySdxR+qkelc2GqYWSvNcsjylWtPmSWvysa3gfTYwt9d6hcqtpGuWJfIHuc9K7TTrrw1fosVpd2dzOcYBkBP5V4/dw3pgudKjlEcVtLlozkGQ4+6W7464NczNp2rajqKKRaWTRklLgSkun0IH6e9bTwvtW5OdjWvGpGfLBNo+iLzwjYT3PmsnLjL4GPy9K5vWvhPojlrm0R1kbHyO5K5riH8TatBJNCdRa4+zoAsuTkeuPWn6F8UNXttUitr5ftVmxyzAZdOBWSw+JgrwkaVMHOKi5O/kes6FoMWhWaohUPjnJ46Ve+z3K534ZC2RgY/IU/Q7y21S1+127iUnnGegq/fTRwW7O3QdhXmznLn13OWc589pbnzX8T7cWXjRLq1s2MMZ3mH+8SOo/GqfwotvJ8QC91GN5LdicMQOw4/Hk16Pb25t7nVLvVtE1GW9nZzCwiLxqpOQMjgDmqFrbPp0P2mSNY1uJiRDn7h6cj8K9yNa9P2fyPShRpSqe062tv5WPNtV8U3F340u2uA6af5xSGI9AoPHSunM8z/ZmtZMusTOFYfKDn+Y44rY1XwXo2sWtzeorLdEGQbX2pvH3ciuc8J69p6eIhp2p2/kxyyeTDcj5yJT13egJPUVfNGUfcWxy1faKi4VXs9D2zwLrP9raYY/vGLALqeD6478c10K20aTeaRl8Y5NZfhbQ00WOZQhDE4B68cmtzdvGQQR6g189WlHnbhscOq0EcAA/xegr5/8AHEgt/ijJNtKeevzL0zgY/pXvV5bG4a3ZLiaERSCRljIxIAD8rZB45zx6V4L8U7iNviIjFtqwr8zZxiurL1+8a8j0sp/jP0ZNBOLS5V1yUJJ2jtXASQXltPNDDBJmViGIHyuM5z0r2jw34c0XWtOJivZ3vGTcWB2gZ7gHqK5/VtCfTdUmspZQzKocE9HXBOR+R/KvTpYiKk49TarChjZWTs1+Jl2VybPTo7ZAAqRhS/v3rT8CaG2r62Z7okpEd/P1rj9V1FG8QWNtZh5IkYCQqerZ547iu10bV5tMuW2FldgAcU6sZKLcd2bUpKVOUMP00ueo+LLi2s/Dt213EssQjICsuQWxwPzr5/ldbSUQSK3zEhgO5xkiu78U69NcQRpPOjRKQwzwCR0z681xdz5sjWt2kIkMMxkZwwxKp4IyO9YYOk6UXzdSKEJ4WjOUbcxo6Fcx3WvrHY7gRHuaMjDD0H867yNrsou3c4A7jOPavOvCUyHxWlxGTKrJjamTsU9BuPOa7bxDeaxZ34htLKR4QgwURcd/UZzTxEffSX4nJVxHtYxqSRwutXYto1lCbnJKj2FLpWpifMkcRV0bGCcg0/XrVrmERKFLBuvpVTRLQ2cTxMys27J56CunTlPZvPnt0OiN7HcwzxTRLll2spyM5rmrHSJYNWWQTN5cBzH7Z7e9dKqp9n3sqk4yzZzj8vxqCSSO4RXh+dW/n61MZWTS6nPOhSqS95alW9smvvlLg7DuwT19q9t8F6Mmi6JEpj/0iVRJN7n0x6AV5tpqwR/2eHA2ySKXPTvnH6V7LGc4IxtxxjFebj6rsodDgzCVrRW3+Q7apGSuePTqa8w+LN95McsKOBkDK989q77UdQFpu2gs+CSB1FeQTwTeLvHNvZuR5fmebKV/hUcms8FT5ZOpLZE5fC0/ay2WpZ0zwsIfDiX5lKSeWRJnOMH29feoob/SPsH2CVSt0HBE2eM/T6V3PxB0GQ+ELoaV5zXUQBWNMncB1GPpk15x4F8OJ4l8z7TdssUSDeiR5bPSuylVVSDqTeiZ0UfZ1efETetylrk+jW+fMufOK87txwo9M9/wrL0bWNKbUdsloWBbKtId2Rjriun8SfC29kuFfQbmK4fYVMVxGR34IYd6p+GfhTqv2tm1uRIDGCysEzvbsMg9P/r11e2o8msifr03Plj8K+9lC5uUhbLpk9F2/wCf1o0rUyVSOCRocnkKxA/LvXd+FvBdnqdpKuowNHdRkqGPAb3xTNG8KWMXjj7G4EkduDJtJ9+nX3rN4in7y7Hf9eoyi7p3RJp2gyz2ySrbTMNoweayfEWhTT2slsQcP13dB+Fe0WzIqsq7QqnAA6VnatYxXiBo4wX65JxuFcEMa+bVHlrG8zcZrRnkXgPQH0+7uDEY/tTL5fmlQNo9B9a1tW8Bwm2ea91B7OcBwrQgcKe3P0z+Fafi4P4Ys2ubMiWb7wz3xXm138Sb/Ube4jvLd3TlbgAcxrnnH4d67Ye1rP2lN6GNWpRcuVaRO8+EmiaVdaTeQyW/nr5md0mCTjv9a9A0DwxpWhPM+nWwSWbl5GJLH8a4D4QXNu8cht5U2SklB688fpXpwnHJLH5PQYFcGLlP2kld2FiqfLU93ayPPvivpmmyKJhdiDVZNqgZGSo5yfwBrxG6vpLcLBbxLEg/icklsdyfXNa3j3xVBJrt3FLM7bHb93GmTvHQsewrCs7aS4u3u2UyIyL5W7k+5wPr1r2cNSdOmlN3KwftHUUKW/VnSaIl9qVxFZxMWLHO4j7g7n6126/DCe6gE/2qQOvKiQ9T0rL+HMZSZ22EtJjkjgAV7dDMPJQZGcDv1/zmuDF4mdKVoHp47GVKMkqeh8w+JvDeo6dcfZ7mKRSW+STacN+fWqlvaXkCm4BO5xlPJGAMcV9WTxRzxkXMKPHwdrqDz+NeXnTbO0+IN3YSAJazqJwoOACRyB7Z/nWlHHOpFprYihjIVZupKHvJfeW/hr4rJtorC/Lm6bj5zjHYY/Ouw8Q6ibXSrqfO10XCkHofWvG/il53hnxNHPYDZbuAy8YG4YNMuviHda5aQWNyFjMf+sJBXJ9+azlhPaNVYLR7mEqVOvWUodd0bWo6dHJ4NutRAPmtMCfUjof8+1dH4b8K2VxosMq5DyLnPT2/GuY8Q6ys+gabpcMkUsZk+Z1fqe+a9Y8OWqw6RaxA5VIxUYipOnC/n+BWJqVKUObZt/gea+NvApS3W6sZsTYIbHG7vXJeCNDD6zJDIoW4/wBXgrkHPvXvmvmOPSbqVwvyRNjPr2/WvGdX1UaDdRalEhO6UDA74GcVeFrzqwcepphsVOpSfPuupvTnUfA1u08cbvEMkqhDbh6fWovDnxYt9b1yGz1WwOnQE4Essgxu7Aiun0rxXpPiqAW06eTLIPlDkYYY7H19q8x8ZaDZWOvwRfuVMk4DAkABffHSlTjCq3GtG0zlhF4uST0Z65J4x0dG8mOfeWOF2DiuA+JF9bTySLaMPPZFPyn8z+VOWys9c1Fxp9ukNjZJhjH8okYDt6jOK3dAstLjtryO7hhD7BsdwBuP19aiEKdB86vfsbRp06DU1e66Hl9ld308CWjzCCFgB5sgwPzrP8F+H7iTxrpcdwgaEXYuCQwIk54Ofaum0/xVa2WqXELaXG3lT8MxypAOPp0rQ1vUtGnnt73S/Ls7iJwyvG2CDnocV3ucleKjuaYpLEySaske2sQSeM4PrVcxYcyRHBI+72NQW0sktlDMkxJZQxBHFWY3Z1yQu31BzXznK4niNNGZquuQaVZS3V/+6hjBJIGfwxXzL4+vpde1qefSI5boXcyrGEQscY9BzXp/7SN/cW2gabBCQFlmbcxzzxjH615foou9K0aGexMiyB9wkVSdvft+Ve3l9FRgqq3Z24OPPGolppuexfCrwxqempDe6vHJHII8IkhG5QeNuAf/AK9UviBdHVfE89tZcG3gMO+PqWIyRn2ziuPt/FvjTVL1LOza4niOA5NuYwVxyQ3bHPNdjDa2ukxfvpPNvohkBG4U5ycnuTnrSlTnCp7Spa72SHg4xV5Xu9jyddFv7XVY12Th0YFHCEEH6jt2refXrJLiKNvNDo+xpgP3ZcdV3exr0qHV5LpWnaONHEe1w7YQj1Hoa8gOk6xbteWFuEa0lnZ1mRhnY4wQc966qdX2r99Wt5gnXwv8NXTfqdNrFtLexx5kHkbcrz1HXggda1NGSBdHeyvmS5mkVppJB8gjx0xnr/OodK8q2srW2mXBhVYhKf4yB3HvV6WwiaIyT7VRgduBwT6VjKWnKeg6cZSU5KzK11evHJaz2v2dljIEjKBuPbp+Fd3pniG2ubOOSSZEfoVwTivO20udbZjaozpnDEYOORWQkl984DhAGI2knioqUI1Y2T2KqYWFVWT2PRNW8LMFLH9z6kjg/jXEWelm7vH8uVSoO1WUY6GvRvH3iKGLS3gL5LggRjqx+lcBpl3cRQKqqkY6kjrSw8qjheQ8I6sqfNI1oEt4dscrluASqj9KsxRaYXVIoJFj6joM+prGdZVzkqW65FEl2+7YigHqPb6Vpy36mrgm99TRu49t7AIgCEbIGRzivS/DTxPpsfnNiUj5wW6V5VpZZrz94FZlXoa6K0uJZJltzjYxypYYrDEUueNrnLi6LnFK+xr+PNatLJY4bF0N25IO09qyfgvbefc6rqcjEuWES8dq4y/mebXZYwEYo5Un0HSvQvgtGDoFyckFbhlIHalXpqjh3FdbE1qSoYRpdbHoJLJ8o5z0Feba1c2fhvxrdGz2RfabMSTRoOPM3nBOPUZr0PULY3VrPDGxiaRCgcHlcivnPxbpWreHdaktbmaOR5GDfaOpZSTjJNc+ApRqNpv5Hn4R04tuo9O3c978IXMd5pK3MTbmkclx/dPpW2yqylSMrjvXz/8ADXxjqGk3M6y2U9xFIP3kC9iOjL7EV3Z1fxX4qZoNLsBo9i3BubgHzMe3/wBalXwk4VHd2XcVSjzS54v3X1NPxHrFppt3tW7ijjVPmIblT+Arlfhot7qvii41VUlNs24PNICA2egXPX1rrtK8B6ZbKjagX1CdSGLzH5c+uBXVqohiVIlVI1OAAMAD6UOvCEHCGrfUuWIhCDp09b9SpqME7IVtzt3dSPSmzXdvEUt2BM7ZRV2nng/lxWgc7SDg1BcQ+YC6MAQpGRXInfRnIpdGYHiPw8Nc0wRyTFWA+XB7Y6fnXmY+Et3dXM88UsUMgciQSnKzDHHAr168uIrPTjczSKAgBOa5x/iBpVoERo72eVgC3lQE7fWu2hWrxjanqaqjKom1G5yfh7RLvwDfKLtEeFlLK0fI/lXa23i20mkAkidY/wA/8iug0m9tdZ06K+t1EkMy4G9cHGehrNvPD1jczqViWLBOdhxSlWjVf71am6qwn7taOq0PHvGfwti1bV7nW/CmohZ3y0lrI2wdOxrjtJtp7GxtIJ1JcymNW3BiTnoD6CvddW8IXT3HlWN8I4ZEb5iOc9AK8x8TaBeaBqNtaXqpt3F4nDZU/j27V6eGxCnHkcr/AJm+ChCFW9GWr/I9U8F6Nb22mWxDBwF2vuHU11EWzYYzzIoxkdPauC8La/DDYRJNJ0+9kZ5+lbkniKGG2kdRliN2wEA4+teZWpTlNkYihVlUdzo5LxYrN5pZVAjQu4PoBXzpqPji71Px699BGn7pf3GzPzKh5UnpnmvXrnxpoM9pJbXMpKzq0TIgyeRg14e+mQWWoyC0vJbq3tSxt1aPaRnOQeffrXZgaKjzc61FhcPXjWjaOnX0PU/iSdP8Q+CLe6mKpPKBMhJxt9RXh7aYXK/a/tc9jGu0mBgGJySOT0H+FekahpU954AsJbhlaO2d/kcYAHbPr1q94O0fUrHSbgapoV1dWtyqsjx4DAeuCc9DXRRmqFNpO+oVKSbdJrRPe/4eZ5r4YgncFrouEjfcmeu0YzX1hYLGLK2eBiIjGu05zkY45r5+1rT47G6a/wBKmZrFzteORcMh7qQe9d94F8X2MOhQ6dqF4IZbdsI75+aPqPxHSufHwlWipROvGYeUqEPZttR+86f4gXosvC95JI2fu/L6ncOK5KfwzDrPg+zjuSoVQZdxOCNwOTn2qf4ia7pt14bltLW5SeW5I2Kp5BBGMmpfiBrUGl+CEt1haJ5YAu1ekYx/X2rnoxnCMVFatnLThOMIwtuzyjT9Jms9aNnYTfaYg+4NCx+UA8D86NaTUJdcjhmKy3LLwS3p6+9YC6nqmn6pZMkb2zzRrLHEerRnPzHHY89a7HT9Mvr27/tW9UrGPlBQDIz14PpmvWneLuz0cFOkoynS229Wel+BvDkuk6BPFcbZbqdC3HQA9v1qPRkie5ks9ShVo3Plsrjv2Oa0PDN9e3NokbEttXarc5YdM1keL7HUYJ5LyxDqmA0gPr/eFeQnKU5Rk9WcMajnVlGb1fU831vSDZazcpZRmSLzHARsHCk8VxPiMy2F7bx3FtJAhYIItjAy5PXJ6V6RY6xHbask2oIQm/BfHA+prv8A4j2dnq1z4UhMcUwmvkZHwCNgGSPpXofWHSlGMle/U0x6k+SD+86DwXplxp/h2yS8kkkuPLBcMSdvHT8K2QJkIC/MpPPHNWXGVAAye1MYnI/p1r56U3NuT6njyk5O7PLPj3psWoeHbd5fkngmQxjrnOQRWXpdq9to8NqqjbOo2k4G31J/WtH4uX4u9Y0zSg2BEfPl46emfwrnYZrnWp13yMmnRDYNvBkAJ6+3869igmqEU9tz28LRUKCk9L6v9DRklLs1tpEjTBPle55VAehx61LHaTLC0a33ynKuI8DJ+vekhdLaARJ8sQbCqMDFVJ75nuPLtB5jHIUYOfXir1eiGpSm+WA+LSbS2uEjdXnCkZDyEhv1pz6RYM8XlRiIyFsbCQVGe+OtB0LxBcKJxaz/AN4DOMfhVN5b6xuIl1CGSHbkgOpB96NXtILTesZ3fqXJtBuDF5mm3TzZyNsy/Kw9z2/HNaXhTV3mlh0a8jiZmcxPFIuSjYOP8iq8N4fKVIZSMbmCcdx6elYHiIyW00OpW0p+0wMpYY5xkYJ+lRyua5JfIUXKqvZ1N+nqewQeG9PjiEbRNKgycMxxnvxVW58FaLcSeYYHQ46K3H61qaJqI1bSLW9TC+egbb/dPcfzrhNS8Sa1p2o3NsZPMCSEKREOB6VwU41pycVKzR5DqVIN66nA6jvtohf6mzvuOEAxnPsKt6Fd2N9c+TIgEmFwhbJ57H0rR8U6dJqejSrZx7548Oq+oHH9axfDeksdQjmeFYHCjeSOCR6Huc166lGVO/U7MRi6zq2WxN4svhHqFxDZsyJEpMUanmQjsa27DSYdV0a3u4J1R3j8xlkYDA6kfzqhq2hNJdPMk0SiVi+4g5GRyeP8aS4iFqFtIGTyYovkLfT1PHWh2cYqDMYYitSbk3oN069TTtTVbkkpna4BzxXRefFcDzI2+VjhcenfFcJFBdy2X265tRbYO0fMX3D1zWx4dvd6zW0jcqxKjHb0pzgt0e3TaxFJV1ox5tgdemaMZbGck8Guj+DOoLbavrGkzsUZnE0YLYHcH9MVyuq6jFo93JcX4ZTlUUDqSR/gKdYalDpXjbS9SQ5tbsAMV96itB1Kbj5fkTWUasJUlvY+hTkHO3J9q5/xJ4ctPEM8JuVKPCDhwOea3EfzUBUgqVz1pwwAAvA/pXhwm4O8XqfNmLZ6Xp/h3THe3iWOOJS8j4+dvUk96yF8f6HCi/aHuYY85DPA2MdsYzW/4nTd4d1IMeBAxx9BXl1r4gXTdOCCFLhTEAVxlgcV10aSrpylds7cLh1Wi21sejx+MPD7wpIurWzK3+1yfwrC8b+ObbT9NC6ZL5s8yHDqpwvH5Z5rx83CDVZ5ZohCCMqm3g//AF6jvb5bxlTeEjI2kSsdoyRkcf1rup5fTjJN6nRXyxwhzU7tnSR/Fa80+OSIQPPdAqnmSnCqD1Le+fQV03h34n745Y9Ts3FwDuQp0cZ9/qK4Oz0HSdQ0+8LanClwE2rGVLM+OS2eM9h+FT6Fo9jZKJWmupdgAZ2Iyo9vbNa1MPh5J2WpyUsNWm/ejodDrfi2W7dvtLpFZqxKhjyT6f0rS+HlzZXgv7xpo1bBiILAYz/jXnHxA0e4t7VLiFZJLF+UdBkEE+v5dKxNL1VfDIgkt/Ma4flkYDBHQZzV/V4zpWp9Tvc04umtFbc+gPhdqMcmlXdqZB5ltMy+WOwrp7sSzZVMqH9xx65rx34Z6ms/ihri3maOC4XDxY43dP6V7DLAY0kMEhWVwdufmANeViafs6rfc5cTT9nU5u+p4l40+IOr6dq066XdeR9lnMKwSxhi4A6+pGeOKg8ReKrjxNYWF7qWmSWlzCCjrn5Xz3A6iu3+Guk6Zeazq02pRRz6raznYsgyEX+8B/vZ59qo/Hi6t0Gn28aqblss+P7vbNd0J01VVOMdV1NsDFLFKL1/Q86stRnBeK1jZ3mYCNBz/kV1w8NXqRwtqdxJJNccGKMngds4q/8ABbwxHK0ur36bhgRQqy9fevZREgC7EUYPpWeJxns58kEdWOzD2dT2dNbbnzdruhXthN5bRP5HJWVoyM/iasaboN7PbtcafLHNJEhYoOpA6j/PrXvXiC2jutLnikAO5SOa+edLg1Hwz4rNwglWBMnJPysrdQ3sa1w+IdeDa0a/EVHH1asLRWp2WuapY6r4LtooYvJvLRwZoG+UqR29wa9E8J+KLDXbKDy3EVwUGYXODkdceuK+fbq8udV1i5/s9LZN+5tqybWCA5xg1HpWq3ENnINLKxOsgczMNuxuc8n6duKdTBKpC19f8zjxHsppxjKzTe56F8XEtYPFmnquEMyg3CKPvYPBPvU48KWl/t3sUEgXbtGc56VxmqarLrN+s95L5tyFVXfHXbzjp9a9vs5Le4h065tQvksgZWQdRj2rKq5UIRj1OmpUlQo01BnmVr4T/szXo9P1FAmTmK66qw+nrVH4h+bcXEmnzMJpI5Nh2/d29uPxr0fx+0EttAkoPnB87kOGUV4prmoAauqxuwkVv3gPIbnH51ph5Sq2nI6cHKeIaqS7Gz4Q+GepXey9mnRdqiNTJliFHavQD4IlgtnFpqTC4UfKCvyk+hA7VoeAvEdlq+nxWcJdbiCPDKVwOO/8q0bnxDpNteiyl1C3S7LABWYcZ6Z/+vXLWxFdzce3keZUrVaMnTXupdDI8BaxE8Lw3RSG9V/KkhzyCOMg+ldSVXUpJFI/cnh/XA7V4P8AFKG40zxkXsp8rLIpyjbQGdQc/pXWfB/x9JqjXGlahHm5jOfMzndj3706+Fbh7eBhWcHJuO7scT8U9Kn0LW7i2gWUxy/vUdVz8nf649K1Pg2+o6prWnQaldhrfT0a8t1C53BsqRntjjivbtZ0TT9csnttSt0nibn3H0PrWT4U8GaV4Tmu5dLEmbrG5pPmIA/hB7D2pPHwnQcGveMvb1dr6HTg7uccdPeq2oTpZ2k9zcPiKJC7E8cAU9QQME8da86+MusvFp0GjwSFWuuZSOojHUfjivPo0nVqKKHh6LrVFTXU86tZZ/FniSeeZ9jXknzOTgJED0yegxjk12mmR2skZh0vULK8EYKvDBICyj6dx9K4bU9PubLwXdPbLIJ52RmwCf3API459M1yen4kvLaLS5ljvmYNEYcjaAQOfTPU+1fQey9qvddkjtx2M5aipQ2R6XrjkfuVOxi2Cqjt/wDrr0bwX4Yg0uyhurmFX1Bhvy3OzPYfhXK6ZaLqPi+ySeMMMb5MDIOOc8e4FeqEAd+vbrivLxdVqKguu4sXWcacacdL6sazbSWJ4965DxQYL6K1aa3LZLKCxAOPUV0l5Z+dlxIQ+RjuB+FU9Z0NdQtYYmuXgaNidyKOSa5KUowknc4qclBqR5tr+lxWcn2izldQUz19fX+tNW3i1DT3SRciWMjryCRjOPrXYa1oFrBo4jjVpLjhWfOSeRya4KO+MUz2mSjK5TkY56969OlU9pH3XserCftoJrdHX/B2/abRbnTJ2xcWch4J5we/0zXS6ro1nd3XmzgByMd+fevKLHUP+Ec8T2uqx/8AHpcERXSgdBng9Oor3NG3IGVuGAII7iuPFxdOpzx2Zw42nyz5+kjyU2oh35lVDjIjXLEf5/rVQT+VJH9rhfy5CMSDsD/+qul0uS3jYgZkc/IcrncD71LfmymtpTNFtdSIwhH3R611KetmjoVTW0lcz44YVcMskM8DALktlsUrWUaZVFEkXIQuBz7VgXelTM4awmjBHzFH6Y9MioPt2r2KbZ4JFROBIPnVQfUiteRv4WavDxmvckT+LLiOG3FqgHzYJGMYHcVk6ACmpxyxZDZz689quWunvqqvJuSQnoc5GTW1YaJHZSRNGWZ84KngZ9jWt4wjynfCUKFPke5yfxQ0SXW9PcxuWvGIdFXjp2/Kud0a3vm8FpHdRSrcWMvyB1OcV6zcRRHzRcLlHUqoZMDkj/CsO7WFIFVAS68MVPBHbI/KqhUvFR7HLRglVVVb7eR3nw08VQa9o0ELELeQrtdSfmOO9dlu3N1AI74r5z05v+Eb8W2d9bSN9kMyiUDgc9ePSvoWFoJlSePY3y4Vx6Hrz/npXk4yiqU7x2Zw5hh40anNDZk7RxsrCfawPBU8j8q818V+EjYTT6noqia1JzNa4LMvqU/wr0lW+YbiPxGakGGwARj6daxo1pUndHJRrSoy5onz94kFtc2UJiQGYnChRgj2rX8DeCZtRuo7rUogLSEgxpjh27k+o4qf4si40fUY00y0SYXH74MDt8s55+vOK6/4Wa9a6xoIijYpdW5ZJIj94HNerWrTVBThsz06mP5qVqe/U1tV8IaNqUareWqKF4DR/KR+IrnJfhxaB3Q6hc/Zm5VTgnr0Jr0TaOM849RWH4q12y0Kwa4vZYw5PyR78M30FedSrVr8sWcFGtWvywb1PM5xd6PKNMupUutAMyo0bD54lY8FT6Vh/GPwxplnO1zZyC1TygMMc7j16n8Kz9e8QXGsXl15UbJC7AiNTyFHI/WsnVku/EUckd880rqFG6TOYxXt0qcoyUm7dz2amFnyc++mq7s1/hNpsGst5Vtez2uoIpeKTKshwM8jqa9t8HzzajZzw6m4N/ZzNBMEJGSOjD2IryP4WiLRfEd/eXLSaldJCsdslrHhQuOSx456DpXoNtfz2N7eeIruy+y2d5GsewSDIZc4LDjOScVyYxOc2vu9ex5jjXnDlqKz6HJ/EtP+Ed8V21xosz20skRZmQ88nBHvXJ2tpca1q0pubhnYcyNIdzH8fwp/xEv77U9dE12jRKy7o1xkso6f/XrJ8J6jPbTyajIrNC7lDt547967KdOUaSfU9XC1VFKivjS3PoXRIjpXh6NIYi5RQQo/iPc+tYEnxGf7Y0EGnzzsg+dVAypzXReGZPO0KCZZmYhSRnqB2H6CuE8Q2mpWOprqPlxxTTKTGw6E+jflmvMowhOclNXZ59GEKk5RqK7NU+N/7VlAihlt3iO1kl9cdT7VozzaHa2UN9qTwtHIdzr97gjpXDNYfZ9Stp3vWkuzGJZh/eJB2rgdhk5/CtW38OLrai2mO2OM7y2RlevQVu6VOO2iN50YRjeOiOMtdE8OeLPFl3Ho1+LFgzOgdyGYf7OP5Zqtq/gO50S8MLXLyRR/MGjIZB/vDHB+temw/DnSrORJGmkfYdwXGCPYEdPwrvdJgtYrciCJY1b7ykdfrnrRUx3s9YO6/rqcDrJvnqQT/rufJupB9NnKJGSGCqpGOM9W966LwZ4r1fTJAlqWGdyhSDtcevpXqfxH8B2d1bNf6UohnXlo0Hyn3Hp9K8+0aS20reLu12XTYRGI4z/nBFdcK8K9O9rno4enGrerT2e8T0fRtBnedrvxBMzs6/dVjtQ89f8APavIPFGmGw8WXNvaTLJHNJ+6LjkAnivb/D+raTqenJ/pQlnXCSxM33T0rN1r4baXrmpR3ivNG6nnbIdvA4Pr6Vx0q/s5v2uhnTxk8PNtry8jz1bQ6XobNZ3M1vqgVo3I4WQHrgjr14rio7G8vNLmjC24meRWZ5pm80bR0UdDn3r2zxhpNqmmC3EqqLG32ow+87e5rx57t0LyMSGIwPX0rtoVeaLkjeODp5hFTqN3R0fgrSbrUtP1Kw/sr7eLhNrichVh9wex+ldVoHwn1DQj/aWlawp1NRkQyRZjOP4cg/rWX4H8YvoDO80Kz25T94I+CgGOcmtu5+L9nNvGk27SMeAcGueu8Q5NU1ozixFPkmlC2nW6/U7HwT4kl1Jb2y1W3FpqVi+yWIHIwehFdRLgrhTkE5yO9cf4C0y6ihvtT1BFa41KQSuc5wAMKK2fEutQ6HpM15Ou7yl4TpuP1ryatNOramjirKKm+U098NpASxVI4wWOT265rwPWb9vE/i15hgW/mbVYDjYMCq3ijVtdn1eG6vb5Ua6X93BGxKCNvpWl4as22zSQRM0kfyJt7EivSoYb6vFzbu2ell8FCnKs99kdHZDMgMWGUD7p4xx2HeqFyLO1uHkjtoYbqUlCUiUZPvgZxVm3mVD5LyK02MMm7kfhUWmwoPE1pNexF4pGDYcZHtQtLsUIxk25a2Op8BaC9rNJf3LHew2IpHQHBJrtHZEUs7KB6sQAK53UdQv7WMy2sCSdiB1AHfipdVs11bTIVu5Fzw+3HfFebV5qkuafU4KrdSfNI17d1lt0k3Ek9DiklmEYCk5JFULAm0sEhLqDGcDHIIzxj8O1RXAlF9NI8mIVGAOuPf8AWslG7M1C7KV1ewyPNbSlWUMFIXr681xnjfT/AC5baeOJgfuEH25HT/PFdZaWklxK1xaRJIGOSznAJGRn+dYPiu5uLfzFukRyP4AThR64ruoaTSid+GfLVSRyV6j6tplymxU2r26A9eK7z4d+K7ZvC9tHqUkn2mAmE8dQOn6Vx+mRgQNJIQEc7sA8muevHl066mihU+WzFx36111KMaycGdsqEa96fZnUPq72l6wCAYUBlcdSK04b77WrNw285Zt2ce1bD6VYaxcXkjN/q13cg/Njvnr3rE0XRZTCbyMlbB5RHIGUqQCcZH4/zrPng1fZo5vaUZx10ZYW7trKAmTKjJYIw+83+AqxpB+1wEySEQuwaQg4yM+9Tav4BnuJke1vuMDiRRn6HFYWlibS7+5065UNIDnB/TFKPJON4PUUVTnC8HqifUtEsorxn0yV7SQYJkjbG4ntt70kEHiS2gN1LHHfWajLeWwVwPXFbNhbv9ohUIvmu2AW5P69OlR+KvE+k+Gri1gcyXF/yskMTA7Aeue1PnnJqCV2ZyxTh7stfUz7a7s9SimnZGkdU27JThkPuKrX0Nu8kNvb2yiaVVVXjQ5bHUVJqMllq9t/bOgMYplCiSA5DOp6oc9x1H86NH1hrdhNZgAlSpVl6jvVpO119x0wftI89M5/WLB5LCePDiUdPQgV3Pw18Ti/023s5BiaPEeRyTx161ztxP595LFIAxY7izDGN3aub8A3w034hQwSEpFJKyYzwCRjNVWpqrSae61OitR+sUJX3Wp9AmNy6MrFcHJxUjBUXcSWI7ZxU6hTzgc9cVGIuOrflzXiLQ+cuc9rWm2upQyXFxHuMSkgA5J7457V5BeavHBOb3SWFrPFJtLwnJP+8D1r1L4ha3J4e0GS7ttjzlhGkXHzZyB+HrXiWgRzXWp3FxfEtcyPk4UAZP04BzXtYKLdNylsb0+b2keXqehaVqnjHxKqxR6ilrATgukYDkdz7Vu23hLR9LD3+rmbU51OPNunL5PYAGqGianNpqGWJCHC7QNuRirV9e3uuYWGymkjXJ/doQCfr+FZzUua0fdj5HpTg1K0bRj9xUudOh1rVIZlsxFbRnDvEmDgc4AHU1F4budN0vxLeNqLCOJ22o0y4xzxnPTiu+8J262+mICgE3O8dx9feuX+J1np66ZePEkQvHhJPqeRzUQrKcnS6bGca6nN0emxe8Q2FvZkazpLW9u4TLFFG1vf0Neda94pfVGtZ5l3WsMqy3CKQFXnHSn6ZqUy+G/9LJ8uBflLZO72rgdbb+0niV7VrWHdkiPjepPqa7MPQSdp626nbDDypQbtzOOx9BTz+EvEWlw+dNZlAAY9zBWRh3B6g/jg1zdv4f0xoZNN0nyXeV2IIw3ynq34814beQCyNuIN724LB4mYgKD0OR3zW14T1W80nWUubRz5EO3ZzwTk5H5VX1OUIvkmebhoP2rSTUvM9Vso9b8G+STi+0tQd+1cMh/p/wDrpmu/ETSdXXTYzaTuyTb3gC5yQCAAR2556dK2tW1OTX/DzNDMmZ/vRp945Hf8v5V4vNp81rqMqJ5jMrgoI+GIz2/HOayo0o1XzVFaSNpxlODm4++u3+R0z6q17rckdxZJYPHIHKZDHGfUfrXqfg8qYZ5sHeRg4xj8q8nvtITw9p8d5rl60l9cEtBDHgkL1w3vXffD/wAQRalFJHGjj5QSMYxjIOf50sVFOneGxKqSq4fll8SO4CJcEclWPAz3NWdkdshHO4DOPXNZ/mMrqYA8iqfvDkD6VBJPNJKPMVic98dP8/55ry+Vs43BvroaKyF4FYDO49DjFeJ/FeS00W+SOeEzecMRBf4cE5z+de02suYwZOIwOoHNeafG7R2vrWC/s0bzrZxhgBkjPI/WurAyUaqT2ZpRqTpt+z36HnkNs8EKahpVxNFKDghgeR6e9eieE/HEt1pQtZZI4buPILM2N3GeOeteK2MGoXdnqEzLeNJauBbhW+RGzkg+p4PNbaPs1CynYiNZ4Vkl3HhSRyf516tahGatLU76eJ/tCnJOPvRPXfGOo6ZpngmczBLrULuL5SWBYZ7j2HNeMXKP9jjdl+crtzn+I11fji8tdXvbaDTWE0UEKp5gTbuPBNc5PCIdNW8uJsmB9uwDkH1x9cVnh6fJHzZ3UIrDYdznfuzpvBfhK812ACT9zZzxkNkY7dOucdK0NE+Hl7BrKfbFSKEvtMoGAoA4Ax16VyXhvxNqyavZ+RFL9mEymQQg859D+tfRqYubPdan5cfxnJzWWLrVaDt0Z80nGfvJGjbxRxWyRoMRooAx3Fc/8RIwfCt9IY1dETeR7A8mtG3M4kQCUMxzyRkE1H4k2poV09zN8kaEtgdfQV49NctRPzFyXlyrqfNvh8PqOrJLcf6uIM6KQBxyV/nXceHGI0a4WMr5xlYqG9fXiufj04XGjXtx5rx3t1L+6AwMLnrW58PGjgnubGQbygyN3PHc17tZ80W+x7jpqnRdKK0VtSqnhzWUvfNf5VLBi2cFOPXrXT2shvL9bDdklQgc8478GrMl7Cd6w3HmyLwWA3cj+nFZZnks9XivGVd5cDag+8AewFczm6i13OTD0lqkdgp+wxrEkxcKMZPU01ryXYEBYgnOP/r1PG1tfxSXELBAiklW4IPeq0Nq967FpjHCpIUL1bHXNcWn2jO6W4pu58AFSxBGMr0p81/PNbMqx7owCGUDrn3pklhdWkDyGJmVeS2/O4etQXV9FYabM06hUZgVK9c/0otF7K4rKXwq51GmXFo9lEtsyoirjy+hXHtXG+ObNNU1O1lsrhSYoysuORjPfH41hXWqTy3UM1uY5IEJwHGByOQTTrUG0hlbdt8xjna33STnjFaQw/s5c99TSFD2L576mNfahFp9zJaovnNEMswOB+OetV757e4aKWORUDRgkZ6nJqTWLK1WZriUyO5bKx46ms2/uoI5wL5XMpUELEDtQdh0rvgk0mjbDOUJOpUdkexyaXeXdg9xbXdvFvjISONeCh52lj+X4UXN7NfaPBaW1m6CUeVI7DhDwCR6mqSazp1zp6Payk3PKbFbaFPuKualc3kGmQvAqJCBjcxO4v7e1eXaV1fe55vJJaSRBqpvo9QgjnuzmNv3TgYDkDOD6E1z3iaOVb2HVI5A7Rbt7d+vp9a17IveSpHIwlbzPMZh1DYxwa6J7DdayoYwLfyyHBXJIxWiqKk0mbRqexkm0cvod0byNdVuSzFW3eWB973H414p4mj1Cz1G8W8tHnupJnkjZ85cZ4APp3r2doRHoV1crMqG0UhIiecYz07niucg1ZtVlha5iYqvygsOh/HpXbhpuDlJK6CeGeIvKHQh8A6bPaeGjJeBI5biXe0Lkkrxjmr1/ZSAyS2MuyVsMUPKOcenb6ijXLpdNiWCCYKGXOevXt9c1X8PvcXrlXkJt9nzN1Ofan72tRl0qvsnyRJLW4gv7GVHhMVyhxIh42t3x+FcT4usbjSruHVrWT5hMCvYqRyD+Nd1rcKabm5toAoRQZQX3b19fTIrL1q2Oq6HNHEASQGU+uOR/hVU5dVsz2MPNXutnue0eGNVi1nQbLUImDJPErEgdG7j86084XqCfWvF/gN4jeOSbQLwjbky2+ex/iX+v5165dQ3UvyrIqIT0749K8etR9lUcDwMVh3QrOm9v0OK+MWnm90BZrcBpY5FJXrkCuf+H+gNeRXUzL+8Cgqr9R9Pxr0OLTsSl7geYhBUK3zFq5+w8Na/okk13otzbujZ/wBEnzyM8fN2NdVOval7NPUuEowjo9TFu2ureRogvlur7TmtvQvED2TKlwNxYc8Y/GsjUNTfWb90ayktdUiwJofQ+o9c1WuBKJNjghs5HHQ84rdxU42kj0OSNWCU0X/if4hu7Ozt5NKZ7SSbI3n/AJaf7I/x4qbRfBceu6Pb32rX11NeToCTnhPYVieJp21exgjugrS2koKqF7Hv+Na8vie6bRWsNHVLaZY/L84j7vXkD1pcs1CKp6PqzmjRqxVqe5y99pyzahPYRu/2WAhZWQYUkd8471ufD/w3YazeX19dr5tvbyiG2Q8dBncRj6VLo9k1toLW0Uke+4DGVpDuYse/P1pfC+qDwuDb3DRMjYZsnn8KupKUoOMHqdVWdSpBxg9To/FdnodlpU8l1ZW4JjZVZYgDnH0rifBfhI3ulW8M8fkrIS4cjBX6fpWle6kfF2uQwgpFYRuAxJwDznFdr4u1htC8NzX0EaNJEFWMAjGSQPyxXOpTpRVNfE/wOZSqUIqmvil+B59r3hd9GsvtWjXEyvE2Jgz5BPpiuV0LVLVfE9nfapEfs3zI6qckEDAJH416D4f8JJrOny6jrrfaLq+JkRN52xg85xnrVDxJ8L5HYPoBjjKrzHI2AT9a6IV4K8Jy17nXSxNKN6dWWvcyvibZW3iHT7S/0u9G+FsrkHPPXnH0qp8OlTTtTKXLhHl6KmdvuDUcMWoaAy22s2zxA4G8glSfY9KopKx1N2gk/iJAJ+8Petox/d+zT0NaeDp2bi91ufQlu0c9vGVxxg4B6Gs/xCyQQLLkBxwBnH1rE8Ma4lzpKyNKsYiHlszcfifer9whv1WdD5qEYBByCPb+VeP7NwnqeJ7L2dS0uha0W3ElorsxwR0/z9f1rmfihK+nafFJBGW3bg24ZDcfd5rpbK4+xx7JCOOg6Y//AFVleKobTXdPeyuhuVzlWU8oR3FXSdqqk9hNT5rxPG9c0bQdRuYtS0/zBFcxb5LWOTYFkHBDDB96r3F5bwHyk05boRvtZumAo+6B/npXWxeGlW61JLRnkkRPkTHLFccD9c1554kt7iO6BtScO24wsCVLZ5+nvXtU5Rl7rex6KpVfZf7OrTe/c6K31TTLq4jsdNs7qyldN8j3CjG3IwR7VveJdA0q88NGGxjebV2585DgOx7Y9v6VmeCPCWs+KdSl1O9f7NanEbOQR8o6IintXuOlaLZabGiQxAuo++wya48TiI0ZJReqMqlZ04pVneXVdPmcd8MfAMHh/S0k1LNxfuxdg4GEOOgH07+9dzJG4GYMAZyVAxkVNIVTdIx2gDB9PrXGeK/H+n6Z/o2msL3UGHCRHIX6mvOcquJndas4KNKdWXLTRs6nq2n6NJHJqNzHCmCQWPP5V514r8SXnjJ/sGhwSJpu7Ely6kBq5ebUPtOqPfasVvLtj8sQ+cJW5Brmqrpr+RpVwI34R/LKge/vXfTwqpNS3f4HrUsJ7FqSV5ee3yLNrYLNPZ2WzfFAvlkbep7k/lVPxZYP4f1a31G0QJAfkkUHoDxVfw54m/s25drpG3vzukGPyrofFWu2OtW8McRZmb5WyhCj861fPGok1odNqlOqote71IreKJYQtvEpWQh9yjBbj+VQavDNLgxq0csfIZfXHbFVrC7bSytpclmtTxHIRjjPAJqfXdYls9Oll3FlRflz3OOmR2qOWSlocc70Jc3QteH7m4UPFdYWA8NvOGcn1Heuk0S/tjJNJA2UBKneT+X6V4fpviXUrq5WRbpnjPzMhHQZxjB/nXYfYb0sPKbEb/NtLYGTVV8N/M7XIpzp4pybdj06XUoJtysyLC/BLNjGO1cp4zaFtMRopGmhHClTkK1YD6dM52vcAKGxnkikm0qdN6wzK3bB4yP/ANdZQoxhJNSN6NGlTkmplHU9W/s/w6jQoPNJ2gnt71gaT4vu3cNqSxiPORtUgt2z9a6i+06GbTFtZ8q/LBgeh7Z9q5a28MvPcRBZ0uFVQv3flXk12U/ZtPmOStTrTqt09jr7BoNRunlL74wPkyMg5qPWPC9tfXYmaSVH2BWEblBx7VauZYPD2lwwooww4bbya58X+q3uZrVJnjzjODxWSUnrF2R6H1f20U38PmXY9+nXrKwAI9ec1v6rrhu9Oto45m89fk2gYAHrUOq263aI6hfMOMgHH5VhOrW82yVcOnahKNSze6HFRxFnLdHeaIJLG3WR9pdMfMByOOuO9bK+Ir8M/m2inKjZhsFm+lcp4fu/ttq8xBLxN9xTjcMcZruNC08KHuJ/mnkGd2fug9cVw11GN3NXPLxEVGT51qVbXQ0ktGa+jje7kbewB6e1Z91bqySTNHG0UbBdoTaRxj866m5mS1DLk7yNwA6/hWDd2V1O4bzisRcOq5wDis6c29WzKFRnG+KdGaWxEseWKoGKD7yj/GsvR9UMMEVsqKIh8oPQj616SzTX93O0kUUUixbQhP3uetcn4j8Mstuby3UieNN8yZ4wa7KVZSShM7cNUpy9yotX1HtbCaAtz5Q/8eH0rzfx6+qeH7W2udNkYmxfeYf4ZoD2PuOn5V6D4cvFmgaCV9sq4CgnlqTXNMa6tSsaruj+dWfkMfQ57HpitqcuSVpbGk4tXpN28/yZ56FmX7F4k0UvCZQtxtGcqcZr2vwX8QLHXdLZrz9xewrmWM9+2RXI6dClxYRPFGihV+5jhMdRj9K5bxFpy6VeC609mjST7y5xg9SPp060p04V/dluup01aUcVD2cvjS0Z7xZ63p9xMFWdUmY8K/ynHtWs0gA5OfpXytrF9NF4f+1+c32jeFVd3T2Fe0/CLxRHrnh2K3mZhqEA+ZH+8Vz19648TgXRj7SLuj5v7Ti90WPFun3Vvrdv4i0+DMsK+VNGw++gzz9ea569ubzV9R8+BPvHoq9BXc+NPEdnoOkSNckPPKu2OEclieOlcXpXjZLq0SPTtMa1Y4V5HwTnjp+tVQ53Dm5fK56OFnO2kbvodZ4e8L28ViX1CLfPMdzBuoqnqngK3lmWWwmeFj94Z4NVdP8AFd0175ZQMAfmxngV3lvMs8CSRnIYZrGpOtSlzN7kVJ16MuZvc8p8ReF9TTcyozxJ12n/AArmdNiAneC7tykijOG6175I8auVLAN3HtXG+O9DtZrRLoR+VOr43p1wc8H15xW9HFuXuSR00Mwb92aOH8J+HbbWdRuVupJEhRQ6KhPXPauwl+H9vc2D26XV1Hn+9KWXHbg9a47R9Zm8N6l58wPlhdr59K6/Tfidpt3dlTDKLbcEMyjIVj61pX9vzc1PYvE1KznzUnoZ+nvqfgvUrWHVszWMo8rzUOU/2T7H+dekWN5BeWyy28gZcc88j61534o8eeHJ/tWj3e67kkXcuxcheODk9KyvA0d9rFoH069RXQFJV34IweOPp/Ksp0XUh7Sa5X+ZzOMcSnKbtJbnp2raZYanpskGoqjQyA8k4K/Q+1eAeIrFvDeqzxK5v0Rl2SBtoGfX3xXp0vgzUruR47y/dk6gq52j2xWT4h8FzWFneTmQNamPcy56N+P0rTCyhSfLzXv0OnBzjSvBVNzz8apLFZmOcn7HJJvdT6dBn6ZzXoXwr1S63XGl3EcSQRxBo2X1yc8fQivPtGeH+1Y7fU4vOsmk2TKe6Hgk49K9M8BaLp+n6zrdpYN9oaCTasrPuYIQML+GRXRi3H2bi0RmOH5aymtrHXxrFMC6uN/3SCe30qstssIzKM4JH0zV2JSz+Sqojudpbv3q4NNj2YeSRmP3iT1ryeaxxOoonJ+IoItH1bTtQgZQ80nlyKD1HriuN16wgF9cw3YAkDb454yF2Nxz+NdB8VJYNLjhkZ2ZnQiIEk7SD1/UVU+HER1PVJ49ZiMuIFkj3jhs5H6DFd1J8tL2rOynXjSjGbd3Yg8O+MdV0u1W3nt7a8QjcHE2w5468Y98VTu/iV4rurp47LRobOFM5lmBYHnHGcVn+JL7SrfxnqOnaaRutcM6dVXI5wfTmqFqLnxBerbROxgRdpznB9hWyo03+8cdzqjQo10q0UkupT1TWfEevTzLqWo3MkanHk2nyJx24q7ovhqTYhmJRX+VkH5ZPrXcaf4fGh20MVxF87/NG55Gccg1evZo9J0ySeMIZmwRG/3WHoKTrpe7SQqmNjCNqK0MG1trHRNLuJhal2j6Ecknpgn0rko/iN4j/ttonazS1RiDbeXuQr2GcZ59a7zwmI/EtldebhCpAZF6E5P6Vf0f4daPp+rG7eEzTFxKoK8KR/8Ar6VHtqVNyVZXZ4+JqSqyUkypruio6rcXEUYWZVwhB43AcfmTXnviT+zdMne3srmRZYuJNrZjJ9PrXs+v2VxqSTorjagHlBTghh3rxAeGPElldX0F5p8slopPk7F3mTJyTn9aeDmpL3n8jb65WpxXIzZ0y6MUSxalG81nONis44RupHv1p97p032J1s2+0Wmc+W33lI7qT/Wrek6Vdp4Qh0+9UqRI0wJHzBumT9BiqM+ozLpBKNIJ7dikwXk4xwQfTvWt7y93ud3tXUo88lfuv1Kuk6fYW1550sjm5yAElTaV78f/AFq6dnR1++q7hj2FZOlTR6to7S3hD7CUzIv3hj+dT6R4In1iRTZSzWtuPvOWPH0FTVa1c3awqVOhyc6fKiaW4VAGMiqccjruqjea3ArAQANKBjANdSnwm09kP2zVdRmYHOVcKM/TFUfFngPT9E0S6v8ATRcySW8Zcq77ifpWMK9CUlG9yY18NF6ts5qwtLjVJi1zJgZyEZsZ74robO0tltyzTi1gQ5JAyQM14TpF5q8+uSSK90BkErvOBn+deqNJLerBAGPm4AbHQnua661Jx6m9GssUm43jFFrVJYtcuxZ2gdrOE5kuH6tj0rYWx8lESAmOMAYBHX3qSztI7O1+VWAIxtH4c59aillTeTJJJuPtmuVyvpHoZVJ865Y7Iwke+0K/Ola6m1s/u5SOG+hq1qdt9qBlg5KgZr13xBoGn6/ZG2v4Q6/wupwyH1B/OvJtT0u/8K3i2moEzWchxBcr39m9DRRrxq6rSXb/ACFQxKqyutJfgzGt7i4sJN8RIl5H1Fej6b47shpKtMrLMihfLA6kcViaZpUOpwnzVRwnOA3b61hXmkNbas8ca4hY5XJqpxp1naW6OifscTpUVmj0DTdQa7uo77UWVY5QfLReqr2BrZTVLKZg8rKqBj1bgAen5Zrl4ovMiKKgZXVUZRj06CrkWl20csu4BiDsIDZIGAeK5J04vU8qcYuVtjX1nyJprKW3C+XuPzI2Cx7D+dVpr2KBXhuwWlkU5Qc8ds1i27xLr0XnXAWCM7whPLHkD+vSt2+kVjJe2oHmquPQ9MYo5eW0WNw5LI85sNKuY7/eQBGrDkg856Vv3VzYWsqxXGoQCYtnY7Yx3PFXLnUAY/Od4pLlU9OA2MfjXhV7b6hNOrLb3Et6JC7BIyxfJwR716FKm6+snaxeKxk202j1iSSGzuRcRyK1lcOA7A5Cs3Qj2Pf8KoeJtJuL2MiIZMZ+XB+8DjH41leEdP1Ka21BdTgkhtplKJFKckMTnI9MYrTsvEVhothazaxHLPvDQmNDg717n0/+vT5ZRl7urR10MVan7Z6NHDSte2gMcsEUjwSBwsiZ59D+FaOm3cmn6lZeINGaG1WAEzxs5+Zu6Fa6bSJbLX7W5uUjKpuwxbllPYH/ADzXL6zCukXF0VhWRSmQG6Z6g/hXQpc94MMXhqeMXt6Okt35/wDBPX/BOh2evmTxDfxee1ySY45PmCg9a7C10bTYDmGziTB4G39a8r+B3ju1uNNXRb6VYpI3byN3HBOdpr2fjHvXiYpVIVHGWn+R5decua6ej29DntZ8Ox3TedYsIJ8Yx0U+9c/Lp/iKw+W0y4xk7W4r0E4xkdaGIzk4Az1qIV5RVnqOGKnFWeq8zybWbTWNLl/tG482aVsSSBWJG3uPwrrxqNr4ghtY9KnjbK733HlRjpj1yaxPiP4wisy+l6bH9qucB5HQ5WMc8H3ry6bVIrHSm1F7qS3Z38tI05Jb2rvhRlWipSVn0PQjT9tSVWp7tj0XxJpltHMIZTFJK43MJMD/ADxXMaVpNqZGtLV0S3mfdIsXr6153ZeKItSv1hmglcSShTI773yfQV6JokS+HPEl22rTfYo44xKu9cbwOcCuh05Uo2b1NKMqLg5Qkm15HBeKdA8t7g3QldiQqSocbsev4VY0Oa+06KGe1lnhuYh+7uA2GI7hvWvQZfFGgeJdMXSnT7KXJKSOBvduwH+e1cpbxCF5Le4kRkiBxJ1/D61tGcpR5Zo3wqpVpuqlZ9ezOm0T4rahZNIur2wumLAHZwRwBkevStTU/iXp2s6XPaS21xbrKuCSAQD1rE8P+CLzxDpK31qsMEbcR7urY6muWs9D1K91p9JtIQ95GzI+5vlXHqa5vY4dybW6L9hg5zbWjj57CmZTe5VgwcMoJBAzjg8/lXdeA76aC0leMsL2AnajMMyw9QCfUdK5TUvCOu6PEJdQtv8AR423GVGyAM459qvi5a01mztdLimlnaMPNOAcDJ6L/wDXrSfLVjaOosbKi0qnNdPTuj2vS9V0y8tIZoZ4wxXdtc4YHHOQe9X5bqCKMyPKgQfxZ4ryi4tY7W8eW4CzoybieMAn9KmuZJbuOEQssducblduMV5rwqbunoeY8Cm7qWgvjK5tdYvbS4ul3WKylCT/AAjjn2p3xN1dfD2nafa6CpgnmYB5oeSkePX1PGKyNdkgjuI7eGRWV+HPvRcNcbnjt1DRbMuGGQAB1yeldcaaXK+i6HTVwinGKTtZM8/0fQHl1OV0EjTXX3SeWbuzMa9g0nTYtCs4ltCN2zdvUclq5jwO0jalLdBUEnMSbhwo4z+Neg6jpl3c2MdtaTxiRQWeTbjP0/Sniqzc1F7GddfV4KhHYxtf1mT7MhnAdlBILcYGK57StXg8Tar/AGRMcTAYG0Hp65/pWnpvhPxFJeQW+s3NtNaO+5sZ3KME8e9dp4e8LadoVxLLEivcP/y0ZRkD0rnlUp0Y2Wr6WPOdRvbYy/DnhyDw4LgtLiMjOT94nOa6KwJuizyeaEXhSRtDZ+n4VanjjkciRQy57irCJ8vJGRwcdK8+pVc9ZbkcysVVCRziPbtXqCe/NS3Dqu0KMuegHc1JLGkqYY9e4rNibY7vI3CH7xPSoWuoLXUzvEWnxxwK5AZpHCMgH381514j05bSRpUHlvHw6ngmrfiH4iyQ+I4re1tBefZmYbAcDp19z147Umu+MdL8T6CFhga21EYZ42HIGccHuK9WhTq0+VtaM7MJXcaqgtTPWNEtI5dp3SEFRjGemSMV0+k6w2mwgiYMjLjY3RT615TfXN7PrSRQu+YSECgkY7M34nP5V1MVnOYgkyncBy7ZOfpXTVopxSk9zvjONfmU9kzv7DxpbfavJvnjVSPlYdM1Y17xLpYsnht7uGaVztKjsMc15lPpUghDFlbtg0y03WNwd8YRvda5/qlPm5osX1KjJ80H8hZ9JtbSSW8tYzG7/KPftkenWr/hm1TzZppcFvupz371V1S4zCPNYs7MM85AHtV3wvrOnRWstncDcWPmeZjIUen/ANat6nM4GtWKo0Hyq12bN1iRCuCGAwBmmJFGwLNAZSf4iKNTmi023a/Yh4AuVzwGB/pXn2o+KfE6XJ+xJb/Z2AZQAvAI6ZPWsaVOU/hPLlWjT3PpG2ljnhEkMgKN6HvTdRsrXUrR7a+hEsLggq3b3rhvCmszxxRKACkgDbSfumu+tmMkKs3UivMqU5UpaHNVpSoyszy7UbO68F3nloxk0u4O2KZuTGf7rH+tRsfOlVgBk9OvevQfEccF7Y3NldQiSKSMjr09xXmGgykxyRc4jbrnk130J+0hzPc7qUnVg5vdHQfa106bznjEqbfkHXnoDUmnz300DliYVmLbg4yQPUVOiJp2hteFFnlzuIk6YA3Ae1ecSePtYl1O5kYxeRK6xmHb/CfeqhSlUvyo5alVRlZndRaAZ9S/tCE+YIjgtjnj0FdDb3Frdwyl4wSQRIFHSq9rqbWWnyeXErHlgSelS+Es3PhrzydsskruzfieP0rnnJyXM/RG1SUnG8umiOb1bw9FqKXU9hIYJo2AjU8h/b+dYOhT3EF1LbXTFGiJ6rjBHvXoD2ws5o5VbcZDgjGAMf8A6q8/mnMviKSQjBZjnnrXXRm5Jp7Hbh5ucXCWqOil8t4nk2Ntx1HeuU1LQIdXvpbJj5bXGJoGbs3Q/wBK6u5uzHarlQ2U5HQcAdq5rxTM0NtBfxfJPbyqybeO/T9Kuk2noRTipXpy66G/4P8ACCeGNKuLK8Zbm8uiJHO3AUgcBTXM+LLJLiOWQjY6Nswxxkd69SlvWuNEt7p1HnSR8t6cV59qUa3cF5vzna3J55wef0qMPUlOTlLcnAydG76I8z0jQ5hdPPp37u5tphIOfvD0x6/4V7JafGDw5Y2KQ6xdNBfxrhoypOT25rjP2f5Te60xuAHCwsMHnoetd58Tvhf4f8UabcXMlutpfRoXFxCuCcDuOAa0xU6c6vs63TqcmMjGnLlprSVpLyuZmmfEK+uonubVI5onOUR26ZNZ/iHWNfvoN97ei2hI+ZIDj5epOay/gh4cjukmtby4aWGCc4G3BYDsTmvU9W8PWUOi3MSJ95GAZuStZzlRo1OVI3lWpRScY2k0eS+GfGOi6U1zbyWE7/aFHlyTAMCe5J+tdn4R8DaL4l8FWkmsQNcRyyNOm1yu3qOorzW8sIrq4hUkqrs2QOmRxxXrXwnv3t/D9xprLvSxlZEfOCwPPT2zWuLXs4c1J2fU5fa1KtOUX5G34c8B+G/Djh9L0yGOQch3+cg+uT0rhfjvYz6le6RaWMYmu5AzLF3bB/8Ar16tLelP4M5964fwhOdZ+ImtXt0oL2kSQwDr5anJOK4KFSam60ne3/DE0qbSlJ7JHN6P8LbnWLi2vPESR2AiwVhtm+YDHTPat7xB8OQ1uYtFYLuU/wCtY9fc16WcbfxpKUsbVcr3Io1pUXeB5foh8ZadpR0aDR0jZiQt00oKRg9SP5/jXU+FPCNpokZmlJuNRl+aadj1J9Paun7UHtWU8Q5p20vvYupiZTv0vvbqcd8VrkWXgi9IJBl2xADvuI/wrgtNttRk0y5nltmtItP2LMpbDtkZyvbHr9a6f4v3Befw1ppB8m6vl3nPYEDp+NZXxMvbpDq9nBN5VvIiK6qOvGOv0FduGuoRiuv/AAEehhZONFRS3u/yRn6Pr+nXN9Lp736lZk2AHBAYjoW6A/4VHc2sy2s7W8qXcCyFVkhYSYCnHzY6V5Fp+n/ar6Sy81kVSTuxnNejfCuE6Pf36LI0irHtVR8o5zyR3ruq0VSTlF/I56GOqqa91WZIJLe1D3l0xYw7jvPC8VN4M1BruzuL+WVZrN2dmQ9Rjt9KreKQLy5ewdUWL5W4X17VDpSLp2kvZ2w2oX6/U4PH4Umk4anquNSpJN/C0dF4CSK+aaRt0O8kxjsfXmvRrJ3jtlVZMsBwD9K8n3PpMsMcDkohLBeg+ldtp+ryXHlyPGAVTAwa48TTcnzLY58bRcnzLY3Jb24g1COWcFYlyAAcjPer9rq9vfny0c7j0x3/ABrhfFmo3DeFL5gwVkw4IHPXpmsfRb64soIJkkLM5875uoz2+lY/VueHM9zyakkmtD18p5MTYAwvPJqxHIjIpB4IqpE5eJC38ShsfUf/AF6nEY37AcAc157S6kNdyRiBuJ6445rB15XWwmMPBbGcfWszx34km8NaS11BCszh8AO2O2a4HRPHGoa1qjQXccexlDYHQceldWHws2udbIuC5ZK5kavpV9pV3enSUE17LN5lvKQSBnr9DS6bYz/a1utTjiS5jjVGjhPGc8knvmup1Rzb6d5kfDyE8+lcP4h1OXT/AC1hH+sbBOea9enKU1Y78Nh40lLEN3tsV7i6uIrqeWxUwsWG0sAep6/nXoulW0xtoJNSh+8gLMDjaSPSuB8HznUr3dcqCHDcehAGD+lemSSSyx7Zn3grtBIxgAcVOKdrRsY0pym3NvcrX1qtsCRICFIIJ9KqzW8coKttUnjcTTbyRpEZTwPlX9P/AK1UbeUzMxbPyEEDPHFYJNK52qDS5rlLU4ZFbyHUZTo4/i+lZ1vDFBfrJIpx/Guetdfd26XMUjOMBRuA9DXOanbfZ7koHLHZu3H+VbQnfQ66VSNaPs5HTaokWsaXDYmU7SpGCoIGPu/04rGbwZrW1FuLa0uCi7VdmAO3txVDTb97e3lcDcY4mkXJ6ECskX+pXIE0mpXKs4DYRsAZHQCphTnF2i18zxMbRVOfIz//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9050=[""].join("\n");
var outline_f8_53_9050=null;
var title_f8_53_9051="Indications for invasive workup in acute pericarditis";
var content_f8_53_9051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for invasive workup in acute pericarditis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pericardiocentesis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Cardiac tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Moderate to large effusions refractory to medical therapy and with severe symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Suspected bacterial or neoplastic pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pericardial biopsy and pericardioscopy (targeted biopsy in specialized center):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Relapsing cardiac tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Suspected bacterial or neoplastic pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Worsening pericarditis (despite medical therapy) without a specific diagnosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Massimo Imazio.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9051=[""].join("\n");
var outline_f8_53_9051=null;
var title_f8_53_9052="Intraventricular dosing";
var content_f8_53_9052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended dosages of antimicrobial agents administered by the intraventricular route",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antimicrobial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin",
"       </td>",
"       <td>",
"        5-20 mg/day*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentamicin",
"       </td>",
"       <td>",
"        1-2 mg/day in children; 4-8 mg/day in adults&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobramycin",
"       </td>",
"       <td>",
"        5-20 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin",
"       </td>",
"       <td>",
"        5-50 mg/day&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymyxin B",
"       </td>",
"       <td>",
"        2 mg/day in children; 5 mg/day in adults&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colistin",
"       </td>",
"       <td>",
"        10 mg once daily or 5 mg every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinupristin/dalfopristin",
"       </td>",
"       <td>",
"        2-5 mg daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teicoplanin",
"       </td>",
"       <td>",
"        5-40 mg daily&sect;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphotericin B",
"       </td>",
"       <td>",
"        0.1-1 mg daily&yen;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    There are no specific data that define the exact dose of an antimicrobial agent that should be administered by the intraventricular route.",
"    <div class=\"footnotes\">",
"     * Most studies have used a 10 mg or 20 mg dose.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Usual daily dose is 1-2 mg for infants and children and 4-8 mg for adults.",
"      <br>",
"       &Delta; The usual daily intraventricular dose is 30 mg.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Dosage in children is 2 mg daily.",
"        <br>",
"         &sect; Dosage of 5-10 mg every 48-72 h in one study [Cruciani, M, et al. Clin Infect Dis 1992; 15:285].",
"         <br>",
"          &yen; Murphy, K. et al. Childs Nerv Syst 2000; 16:4. Shapiro, S. Pediatr Neurosci 1989; 15:125.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Tunkel, AR, Hartman, BJ, Kaplan, SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy; 2004 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9052=[""].join("\n");
var outline_f8_53_9052=null;
var title_f8_53_9053="TREE trials met colorectal ca";
var content_f8_53_9053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TREE 1 and TREE 2 trials: comparing best response and toxicity in metastatic colorectal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"6\">",
"       Percent of patients",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       FOLFOX6*",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       bFOL",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       CAPOX",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3\">",
"       TREE 1 (n=49)",
"      </td>",
"      <td class=\"subtitle3\">",
"       TREE 2&bull; (n=71)",
"      </td>",
"      <td class=\"subtitle3\">",
"       TREE 1 (n=50)",
"      </td>",
"      <td class=\"subtitle3\">",
"       TREE 2 (n=70)",
"      </td>",
"      <td class=\"subtitle3\">",
"       TREE 1&Delta; (n=48)",
"      </td>",
"      <td class=\"subtitle3\">",
"       TREE 2&Delta; (n=72)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Response rate&loz;",
"      </td>",
"      <td>",
"       41",
"      </td>",
"      <td>",
"       52",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       39",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       46",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Time to tumor progression, mos&loz;",
"      </td>",
"      <td>",
"       8.7",
"      </td>",
"      <td>",
"       9.9",
"      </td>",
"      <td>",
"       6.9",
"      </td>",
"      <td>",
"       8.3",
"      </td>",
"      <td>",
"       5.9",
"      </td>",
"      <td>",
"       10.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Overall survival, mos&loz;",
"      </td>",
"      <td>",
"       19.2",
"      </td>",
"      <td>",
"       26.1",
"      </td>",
"      <td>",
"       17.9",
"      </td>",
"      <td>",
"       20.4",
"      </td>",
"      <td>",
"       17.2",
"      </td>",
"      <td>",
"       24.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"7\">",
"       Gr 3-4 toxicity, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vomiting or nausea",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       38",
"      </td>",
"      <td>",
"       21",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diarrhea",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       19",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neutropenia",
"      </td>",
"      <td>",
"       53",
"      </td>",
"      <td>",
"       49",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hand-foot syndrome",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sensory neurotoxicity",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       11",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hypertension",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       13",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Deep vein Thrombosis",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * FOLFOX6: oxaliplatin 85 mg/m2 on day 1, leucovorin 400 mg/m2 over two hours day 1, 5- FU 400 mg/m2 bolus day 1 followed by 2400 mg/m2 over 46 hours, every 14 days; bFOL: oxaliplatin 85 mg/m2 days 1 and 15 plus leucovorin 20 mg/m2 and bolus 5-FU 500 mg/m2 days 1,8, and 15, every 28 days; CAPOX: oxaliplatin 130 mg/m2 day 1, capecitabine 1000 mg/m2 (850 mg/m2 for TREE 2) for 14 days every 21 days.",
"     <br>",
"      &bull; TREE-2 trial added bevacizumab 5 mg/kg every other week.",
"      <br>",
"       &Delta; Capecitabine dose differed in TREE 1 (1000 mg/m2 twice daily for 14 of every 21 days) and TREE 2 (850 mg/m2 twice daily for 14 of every 21 days).",
"       <br>",
"        &loz; J Clin Oncol 2008; 26:3523.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9053=[""].join("\n");
var outline_f8_53_9053=null;
var title_f8_53_9054="Probability of HF men";
var content_f8_53_9054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Probability of heart failure within four years for men aged 45 to 94 years with coronary disease, hypertension, or valvular disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Variables",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"10\" rowspan=\"1\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        0",
"       </td>",
"       <td class=\"subtitle2\">",
"        +1",
"       </td>",
"       <td class=\"subtitle2\">",
"        +2",
"       </td>",
"       <td class=\"subtitle2\">",
"        +3",
"       </td>",
"       <td class=\"subtitle2\">",
"        +4",
"       </td>",
"       <td class=\"subtitle2\">",
"        +5",
"       </td>",
"       <td class=\"subtitle2\">",
"        +6",
"       </td>",
"       <td class=\"subtitle2\">",
"        +7",
"       </td>",
"       <td class=\"subtitle2\">",
"        +8",
"       </td>",
"       <td class=\"subtitle2\">",
"        +9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age, y",
"       </td>",
"       <td>",
"        45-49",
"       </td>",
"       <td>",
"        50-54",
"       </td>",
"       <td>",
"        55-59",
"       </td>",
"       <td>",
"        60-64",
"       </td>",
"       <td>",
"        65-69",
"       </td>",
"       <td>",
"        70-74",
"       </td>",
"       <td>",
"        75-79",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        90-94",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forced vital capacity, cL",
"       </td>",
"       <td>",
"        &ge;425",
"       </td>",
"       <td>",
"        375-424",
"       </td>",
"       <td>",
"        325-374",
"       </td>",
"       <td>",
"        275-324",
"       </td>",
"       <td>",
"        200-274",
"       </td>",
"       <td>",
"        150-199",
"       </td>",
"       <td>",
"        &le;149",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systolic blood pressure, mmHg",
"       </td>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        120-139",
"       </td>",
"       <td>",
"        140-169",
"       </td>",
"       <td>",
"        170-189",
"       </td>",
"       <td>",
"        190-219",
"       </td>",
"       <td>",
"        &gt;219",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart rate, bpm",
"       </td>",
"       <td>",
"        &lt;55",
"       </td>",
"       <td>",
"        55-64",
"       </td>",
"       <td>",
"        65-79",
"       </td>",
"       <td>",
"        80-89",
"       </td>",
"       <td>",
"        90-99",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LVH on ECG",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary heart disease",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valve disease",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomegaly",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        4-Year probability of heart failure, percent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        4-Year probability of heart failure, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        1",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        26",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        1",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        27",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        2",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        28",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        3",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        29",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        4",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        30",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        5",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        31",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        7",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        33",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        10",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        33",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        14",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        34",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        16",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        35",
"       </td>",
"       <td colspan=\"4\" rowspan=\"1\">",
"        51",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LVH: left ventricular hypertrophy; ECG: electrocardiogram; cL: centiliter; y: years; bpm: beats per minute.",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from: Kannel WB, D'Agostino RB, Silbershatz H, et al. Arch Intern Med 1999; 159:1192.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9054=[""].join("\n");
var outline_f8_53_9054=null;
var title_f8_53_9055="Chromate allergy";
var content_f8_53_9055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Allergic contact dermatitis of top of foot from leather shoe (chromate allergy).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William L Weston, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_53_9055=[""].join("\n");
var outline_f8_53_9055=null;
